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Cancer-associated deaths account for the second-highest mortality rates in the United States. 
Primary modalities of treatment often include surgery, radiation, and chemotherapy, and may also 
incorporate targeted therapy and immunotherapy. However, resistance to these treatments remains 
high, resulting in disease reoccurrence and poor survival rates. While apoptosis or cell death of 
tumor cells is the ideal outcome for anti-cancer therapy, this is often not the case, and in fact cancer 
cells may upregulate several pathways, such as autophagy and senescence, as a means to undergo 
alternative cell fate and evade apoptotic cell death. An essential tumor suppressor gene, TP53, 
regulates all three of these processes, apoptosis, autophagy, and senescence, and loss of function 
or mutated TP53 is often implicated in early tumorigenesis and reduced sensitivity to 
antineoplastic therapy. To assess the effects of p53 status on the functionality of autophagy and 
cellular responses to radiation and chemotherapy, we utilized a pair of isogenic non-small cell lung 
cancer cells (NSCLC) expressing wild type p53 (H460wt) or lacking p53 expression generated 
using CRISPR/Cas9 editing (H460crp53). Exposure to the DNA-damaging agents, cisplatin and 
radiotherapy, revealed differential sensitivity between H460wt and H460crp53 cells, in which 
H460crp53 cells were significantly less sensitive to cisplatin and radiation exposure compared to 
their wild-type counterpart. In response to radiotherapy, apoptosis was induced to similar extents 
in both cell lines, while autophagy interference identified a nonprotective function of autophagy 
in response in both cell lines, regardless of p53 status. Rather, the differential radiosensitivity 
exhibited between H460wt and H460crp53 cells was attributed to differences in senescence 
induction, where H460wt cells demonstrated a significantly greater extent of senescence induction. 
Of particular interest was the finding that when the same set of isogenic cell lines was exposed to 
cisplatin, the cells exhibited a similar extent of senescence induction over time; however, 
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autophagy inhibition revealed two different functional forms of autophagy: nonprotective 
autophagy in H460wt cells and cytoprotective autophagy in H460crp53 cells. Blockade of 
cytoprotective autophagy in H460crp53 exposed to cisplatin was sufficient to restore sensitivity 
and apoptosis induction to a similar extent as in the H460wt cells, further confirming the existence 
of an autophagic switch and the role of cytoprotective autophagy in the initial resistance to 
cytotoxic therapy. Finally, given concomitant activation of both autophagy and senescence in 
response to chemotherapy and radiation, we also examined the relationship between these two 
processes. At least in the case of nonprotective autophagy, autophagy inhibition did not interfere 
with senescence induction or proliferative recovery from growth arrest, indicating these two 
processes may be dissociated when autophagy is nonprotective in function. Taken together, cancer 
chemotherapy and radiotherapy activate a number of cellular mechanisms, such as autophagy and 
senescence, and not solely apoptotic cell death; consequently, further analysis and screening are 
warranted prior to therapeutic administration of autophagy inhibitors to patients. While autophagy 
seems to be an attractive therapeutic target under its cytoprotective function, autophagy can in fact 
play multiple functions and switch functional responses. These studies demonstrate that autophagy 
is contextual in nature and may, in part, depend on the therapeutic modality utilized and the p53 
status of the tumor cells. 
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Chapter One: General Introduction 
1.1  Lung Cancer 
1.1.1. Lung Cancer: Overview 
Lung cancer is the second most common type of cancer and is responsible for the most cancer-related 
deaths in the United States, yearly (1). There are two major types of lung cancer, which are divided 
histopathologically: non-small cell lung cancer (NSCLC), which accounts for ~80-85% of new cases, 
and small cell lung cancer (SCLC), which contributes to ~10-15% of lung cancer cases (2). The most 
common causes of lung cancer include smoking, family history, and exposure to certain 
environmental factors, such as asbestos, radon, and other carcinogens (3). SCLC often starts in the 
bronchi in the middle of the chest but is highly aggressive and grows rapidly, resulting in diagnosis at 
later stages and poorer survival rates when compared to NSCLC (4). Furthermore, SCLC is strongly 
associated with smoking (5,6). Differences between SCLC and NSCLC are usually defined by light 
microscopy through hematoxylin and eosin (H&E) staining and cytology of patient biopsies. SCLC 
appears as small (< the diameter of 2-3 resting lymphocytes) and round-fusiform shaped cells 
compared to tumor cells in NSCLC, which appear larger (7–9). SCLC has a higher nuclear/cytoplasm 
ratio, higher mitotic activity, finely granular nuclear chromatin, and nuclear molding (8,9). There are 
three major subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma, and large 
undifferentiated cell carcinoma (10,11). Adenocarcinomas usually encompass the outer parts of the 
lungs and incorporate cells that normally secrete substances, such as mucus (3). Squamous cell 
carcinomas initiate from the flattened squamous epithelial cells that line the inside of the airways in 
the lungs (3).  
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The most common mutations in lung cancer include KRAS (30%), EGFR (up to 23%), and TP53 
(50%) (12–15); moreover, tumors with p53 mutations generally have a poor prognosis and exhibit 
chemoresistance (16,17). Lung cancers have a high p53 mutation rate, of approximately 46% in lung 
adenocarcinoma and 81% in squamous cells; moreover, lung cancer also has a high percentage of  
TP53 mutational hotspot regions (18). TP53 is an essential tumor suppressor gene coding for the 
protein, p53, that plays a role in regulating a number of cellular responses, including but not limited 
to apoptosis, autophagy, and senescence (19–21).  
1.1.2. Stages and Treatment options for lung cancer 
Treatment for NSCLC is stage specific. For patients in early stages (stage I or II), a lobectomy or 
a surgical resection is indicated, which can be followed up with adjuvant chemotherapy to clear 
remaining cancer cells. Radiation prior to surgical resection may also be administered to shrink 
tumors before surgery. Patients with specific mutations, such as overexpression of epidermal 
growth factor receptor (EGFR) mutations may qualify for targeted therapy (22).  
For patients with Stage IIIA NSCLC, treatment often includes some combination of radiotherapy, 
chemotherapy, and surgery; targeted therapy may also be given depending on a patient’s genomic 
profile. Primary chemotherapies utilized for the treatment of NSCLC include platinum-based 
drugs (i.e. cisplatin), etoposide (topoisomerase II inhibitor), and microtubule poisons (i.e. 
docetaxel and paclitaxel) (23,24) For patients with Stage IIIB NSCLC, the tumors cannot generally 
be removed by surgery; therefore, chemoradiation may be utilized for treatment, as well as 
immunotherapies such as pembrolizumab (3).  
For NSCLC patients diagnosed at Stage IV, where the disease has spread, treatment options vary 
depending on the extent of metastasis and patient overall health. Clinical recommendations range 
to include treatments such as surgery, chemotherapy, radiotherapy, targeted therapy, or 
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immunotherapy. Depending on the site of spread and the number of sites detected, stereotactic 
radiation may be given. Furthermore, certain gene mutations, such as EGFR, BRAF, or ALK genes, 
may allow for the use of specific targeted therapies (3).  
The nature of the tumor cell response to radiation and chemotherapy can vary. The general 
consensus appears to be that radiation induces delayed cell death, possibly through mitotic 
catastrophe, and other direct cell death responses including apoptosis and possibly necrosis.  
Several cell survival mechanisms are also activated as alternative cell fates as the cell attempts to 
repair damaged DNA and remove injured organelles to evade killing. Tumor cells exposed to 
ionizing radiation and chemotherapy invariably also undergo autophagy and senescence as 
possible strategies to escape cell death.   
1.2. Apoptosis 
Cell death is the desired outcome for anti-tumor therapies. In this regard, most standards of care 
induce some degree of apoptotic cell death in response to radiotherapy and chemotherapeutic 
options. Apoptosis is a process of programmed cell death characterized by chromatin 
condensation, DNA fragmentation, cell shrinkage, membrane blebbing, and formation of apoptotic 
bodies (25).  
There are two major apoptotic pathways: the intrinsic or mitochondrial pathway and the extrinsic 
or death receptor pathway (26). The intrinsic pathway is triggered by pore formation in the 
mitochondria by the Bax and Bak proteins, resulting in mitochondrial outer membrane 
permeabilization (MOMP) and release of cytochrome C from the mitochondrial intermembrane 
space (26).  Release of cytochrome C promotes apoptosome formation through Apaf-1 and pro-
caspase 9, ultimately contributing to cleavage of pro-caspase 9 to caspase 9. Activated caspase 9, 
then cleaves and activates caspase 3, initiating executioner caspases which activate cytoplasmic 
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endonucleases and proteases degrading nuclear components and cytoskeletal proteins (26). The 
extrinsic pathway is triggered by binding of a trimeric ligand to a transmembrane receptor, called 
the “death receptor”, such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) and FAS (27). Binding of ligands to the death receptors activates the formation of a 
multi-protein complex, the Death-Inducing Signaling Complex (DISC), and recruitment of adapter 
proteins for catalytic cleavage and activation of caspase-8. Activated caspase-8 can cleave and 
activates caspase 3 (26). Both the intrinsic and extrinsic pathways converge on caspase 3, leading 
to mass degradation of intracellular components. 
Under ideal conditions, clinicians aim to selectively optimize apoptotic cell death in tumor cells, 
while limiting toxicity and cell death in healthy tissue. However, this is not necessarily the outcome 
for all patients. Adverse toxicities to cytotoxic anti-tumor therapies often result in lower tolerated 
doses and reduce the extent of apoptosis, while collaterally inducing sufficient damage for tumor 
cells to upregulate several cellular survival mechanisms (28,29).  
1.3. Autophagy 
1.3.1. General Introduction and history 
The word autophagy is derived from the Greek words “auto” meaning self and “phagy” meaning 
eating to describe the cells’ distinct self-degradative process designed to maintain organellar and 
energy turnover during injurious events (30). Accordingly, autophagy is an evolutionarily highly 
conserved intracellular catabolic process through which proteins, organelles, and pathogens are 
degraded for waste elimination or repurposed for the anabolic cellular needs (31). Autophagy is 
frequently activated as part of homeostatic processes in response to cellular stresses, such as 
hypoxia or nutrient deprivation (32,33). 
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The term “autophagy” was first coined by Christian de Duve in the 1960s while studying 
lysosomes, for which he later won the Nobel Prize in Physiology or Medicine in 1974. Using 
electron microscopy, he observed what appeared to be a double membrane vesicle sequestering 
elements of the cytoplasm and other cellular organelles (34); thus, de Duve was able to describe 
the end stages of autophagy and identify autophagy morphologically. It was not until the 1990’s 
that the mechanistic components of autophagy were demonstrated by Yoshinori Ohsumi and 
colleagues, who identified the numerous genes involved in the autophagic machinery and 
phagophore formation by investigating autophagy mutants in yeast for which they also received 
the Nobel Prize in Physiology or Medicine. These studies provided the backbone for our current 
understanding of the autophagic molecular mechanism. As of this writing, 31 autophagy-related 
genes (ATG) have been discovered, coding for various components of the autophagic machinery 
and essential components required for macroautophagy. Through loss-of-function studies, it has 
been demonstrated that autophagy is important for multiple aspects of an organism’s lifespan, 
including maintaining cellular and tissue homeostasis, metabolism, immunity, protection against 
aging and early differentiation and development, as well as its role in disease states such as cancer 
(35). 
1.3.2. Types of Autophagy 
Autophagy often incorporates a broader, more ubiquitous degradative process, but in fact there are 
multiple types of autophagy. The three primary types of autophagy include: macroautophagy, 
microautophagy, and chaperone-mediated autophagy (31). In macroautophagy, components of the 
cytoplasm and dysfunctional organelles are sequestered into the growing phagophore, which is a 
de novo cytosolic double-membrane vesicle that engulfs cytoplasmic proteins and organelles and 
delivers them to the lysosome (30). Microautophagy occurs when cargo is directly taken up 
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through the invagination of the lysosomal membrane (36). While macro- and microautophagy can 
vary in their selectivity for the recycled cellular components, chaperone-mediated autophagy 
(CMA) is highly specific (37). CMA involves the transport of unfolded proteins directly into the 
lysosomal membrane by heat-shock proteins, which recognize a specific consensus motif on the 
target protein (31,37).  
Autophagy can be a selective or nonselective degradative process. Various adaptor proteins are 
involved in the sequestration of specific cargo into autophagosomes through the recognition of 
cargo tagged with distinct degradative signals, such as neighbor of BRCA1 (NRB1), which works 
with p62 to recognize mono-ubiquitylated peroxisomes in pexophagy (38,39), and Nip3-like 
protein X (NIX), which is important in the clearance of mitochondria during mitophagy (39,40). 
However, for the remainder of this dissertation, we will focus on macroautophagy, which we will 
refer to as autophagy. 
1.3.3. Autophagic Machinery 
During the macroautophagic process, a double-membrane compartment (vacuole) is formed, the 
vacuole fuses with the lysosome, and the degraded contents of the vacuole are released into the 
cytosol (Figure 1.1). Under normal conditions, mammalian-target of Rapamycin (mTOR) 
complex 1 negatively regulates autophagy by phosphorylating and binding to Unc-51 Like 
Autophagy Activating Kinase 1 (ULK-1), thus inactivating ULK-1 (41). Under conditions of 
cellular stress, ULK-1 becomes dephosphorylated and dissociates from mTOR (41). Initiation of 
autophagy occurs through the activation of the ULK-1 complex, which triggers the nucleation of 
the phagophore through phosphorylation of PI3KC3, VPS34, and Beclin-1 (BECN1) (42,43). 
While the source of the pre-autophagosomal structure is not fully understood, there is literature 
 7 
evidence supporting phagophore generation from the endoplasmic reticulum (44), mitochondria 
(45), Golgi apparatus (46), and recycling endosomes (47).  
Initial biogenesis of the autophagosome begins with the formation of the phagophore that is further 
elongated by the recruitment of autophagy regulatory proteins (ATG), such as ATG5 and ATG7. 
Microtubule-associated protein light chain 2 (MAP1-LC3) is lipidated by ATG3-mediated 
conjugation and incorporated into the growing phagophore, and is necessary for the closure, 
fusion, and maturation of the autophagosome (48,49). Cargo is sequestered into the 
autophagosome by SQSTM1/p62, a sequestrosome that binds ubiquitinated protein and anchors 
itself to LC3 located on the inner membrane of the autophagosome (49). The growing phagophore 
extends until the two ends join and fuse together to form a double-membrane vesicle or the 
autophagosome. In the final step, the mature autophagosome fuses with the lysosome to form the 
autolysosomes. The acidic hydrolases of the lysosome degrade the cargo within the 
autophagosome, which is then released into the cytoplasmic space for cellular repurposing (50).  
Activation of autophagy is regulated by a plethora of stress factors, including hypoxia, nutrient 
starvation, ATP/AMP levels, ROS, and microbial infection (51). Increasing reactive oxygen 
species (ROS) generation results in damaging oxidation of lipids, proteins, and DNA, as well as 
mitochondrial dysregulation contributing to further accumulation of oxidative stress (51). 
Metabolic stress deregulating ATP/AMK ratios and mitochondrial dysfunction activates 5' AMP-
activated protein kinase (AMPK), which directly and indirectly modulates autophagy. AMPK 
inhibits mTOR, an inhibitor of autophagy, through TCS2 and raptor phosphorylation; thus, AMPK 
activation indirectly induces autophagy (52). Furthermore, under stressed conditions, AMPK can 
directly phosphorylate ULK1 complexes important for the initiation of autophagy (53) and can 
contribute to autophagosomal maturation and lysosomal fusion (54). Oxidative stress also activates 
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and stabilizes hypoxia-inducible factor-1 (HIF-1a), which results in its subsequent nuclear 
translocalization and regulates the gene transcription of essential autophagy machinery (55). HIF-
1a can regulate autophagy indirectly by altering glucose metabolism, mTOR regulation, and 





Figure 1.1 Schematic representation of the macroautophagic process.  
A number of cellular stresses, including but not limited to hypoxia, nutrient deprivation and 
therapy-induced damage resulting in mitochondrial and genotoxic stress, activate autophagy as a 
means to prevent damage accumulation and replenish intracellular nutrients. In this figure, green 
arrows demonstrate positive regulators of autophagy, while red indicators demonstrate negative 
regulators. AMPK is activated in cells undergoing stress or bioenergetic dysregulation resulting in 
mTOR inhibition, which otherwise negatively regulates autophagy by binding and inactivating 
ULK-1. Under stressed conditions, ULK-1 is dephosphorylated and dissociates from mTOR, and 
triggers nucleation of the phagophore through activation of beclin-1 and PI3K complexes. 
Elongation and maturation of the growing phagophore are carried out by essential ATG proteins, 
including ATG5 and ATG12, and lipidation of LC3-I to LC3-II and its subsequent incorporation 
into the autophagosome membrane. Cargo sequestration is mediated through p62 recognition of 
ubiquitinated targets and trafficked into the growing autophagosome where p62 anchors itself to 
LC3-II. Lastly, the mature autophagosome fuses with the lysosome, and the catalytic hydrolases 
of the lysosome degrade the autolysosomal cargo, which is exported back out into the cytoplasm 





1.3.4. Autophagy and Disease 
Dysfunctional autophagy has been associated with a number of cardiac and neurodegenerative 
disease states, such as Parkinson disease, Alzheimer Disease, and Huntington disease (56).  
Alternatively, autophagy has been implicated to have dual functions in cancer development and 
therapeutics, exhibiting both tumor-promoting and tumor-suppressing roles. Mice with Beclin-1-/- 
embryonic stem cells were shown to die during embryogenesis, suggesting that autophagy is 
essential in early development. More intriguingly,  a greater number of haplosufficient Beclin-1+/- 
mice developed spontaneous tumors when compared to wild-type (wt) mice, suggesting that 
Beclin-1 may serve as a tumor-suppressor gene, and mutations in Beclin-1, consequently resulting 
in autophagy dysregulation, could contribute to tumorigenesis (57–59). With regard to the tumor-
suppressive effects of autophagy, induction of autophagy prevents the accumulation of damaged 
organelles, protein aggregates and promotes the removal of oncogenic proteins (60–62). 
Furthermore, autophagy induction in healthy tissue functions as a tumor-suppressive mechanism 
by removing dysfunctional mitochondrial and ROS that may cause DNA damage, thereby 
maintaining genomic stability (51,61). Autophagy induction also plays a role in eliciting an 
immune response through modulation of immunogenic-cell death (ICD) by contributing to the 
secretion of danger-associated molecular patterns (DAMPs), such as ATP (63), secretion of 
cytokines, as well as antigen processing (64–71).  
In tumor cells, depending on the extent of genomic and cellular damage, autophagy can promote 
tumor cell survival through clearance of protein aggregates and damaged organelles incurred by 
cytotoxic therapy to allow tolerance of stress (72–74). The catabolic processes of autophagy also 
provide metabolic intermediates and raw materials, which feed into the intracellular anabolic 
processes, permitting the maintenance of cellular bioenergetics (75,76). Studies by Guo et al. 
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demonstrated that RAS-expressing tumors had elevated levels of basal autophagy, and relied on 
mitophagy-induced clearance of dysfunctional mitochondria and maintenance of metabolically 
functional mitochondria for survival (75); that is these types of tumors could be described as being 
autophagy-dependent or autophagy-addicted.  
Autophagy can also aid to maintain low intracellular levels of ROS that contribute to activation of 
pro-survival pathways, such as Src and NfkB (77,78), resulting in tumor promotion (51,79,80). 
Moreover, HIF-1a induced autophagy may contribute to tumor resistance to anti-cancer 
treatments, and inhibition of autophagy may restore sensitivity to therapy (81,82). While 
autophagy is implicated in tumorigenesis, functioning as both a tumor-promoting and tumor-
suppressing mechanism, autophagy is also induced in response to therapy as a potential mechanism 
to prevent damage accumulation (83,84). 
1.3.5. Autophagy in response to cancer therapy 
Cytotoxic therapies, acting through a multitude of mechanisms, rely largely on extended damage 
and impaired cellular functions to activate cell death machinery. In an effort to mitigate the 
cytotoxic effects of cancer therapies, autophagy is often, if not uniformly, activated to remove 
protein aggregates, nuclear damage, and/or depolarized mitochondria (85). Removal of these 
damaged moieties serves to evade activation of apoptotic cell death pathways and provides the raw 
material necessary for metabolic processes (86); however, depending on the extent of damage, 
excessive autophagy activation can also potentially result in cell death (87).  
Extensive pre-clinical and clinical studies have demonstrated autophagy induction in response to 
therapy (83,88,89). Although the desired outcome of radiation and chemotherapy is tumor cell 
death by a pathway such as apoptosis, it is not obligatorily the sole or primary response to radiation 
and chemotherapy. While the effectiveness of clinical therapy in promoting tumor shrinkage may, 
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of necessity, ultimately involve apoptosis, studies in tumor cells in culture clearly indicate that a 
consistent and uniform initial response to radiation and chemotherapy is autophagy (90–93). 
Studies by Ren et al. utilizing 30 NSCLC patient tissue samples subjected to 2 Gray (Gy; a 
clinically relevant dose of radiation), assessed LC3 and SQSTM1/p62, markers of autophagy, by 
immunohistochemical staining. Of these 30 samples, 26 demonstrated significant upregulation of 
LC3 and downregulation of SQSTM1/p62, indictive of autophagy induction (88,89,91,94,95).  
Screening was performed in which U20S osteosarcoma cells were exposed to 80 National Cancer 
Institute (NCI) anticancer drugs and the extent of apoptosis, autophagy, and necrosis were 
measured. Of these 80 cytotoxic drugs, 59 drugs induced autophagosome formation and 
demonstrated autophagic flux in studies where the cells were also exposed to bafilomycin A1 
(BafA1), a pharmacological inhibitor of autophagic flux (96). The remaining 21 drugs produced 
predominantly necrosis and apoptosis, with little autophagic flux. These latter agents were further 
characterized as microtubule inhibitors, which may in part be due to the necessity of microtubules 
for autophagosome localization and migration to lysosomes (97). There is an indisputable 
complexity to the cellular responses activated by chemotherapy, and of those responses, autophagy 
is clearly induced in tumor cells by many anticancer therapeutics (Figure 1.2).   
1.3.5.1.Autophagy in response to DNA damaging therapy.  
A primary mechanism whereby a number of anticancer drugs, such as platinum-based compounds 
and topoisomerase I/II poisons, exert their cytotoxic effects is through DNA damage. DNA double 
strand breaks (DSB) activate Ataxia-Telangiectasia mutant (ATM), which in turn can activate 
Chk1/2 as well as AMPK (98). ATM, itself, and activated Chk1/2 can phosphorylate and stabilize 
p53 (99–101), which, in turn modulates the transcription of key autophagy-related genes as well 
as damage-regulated autophagy modulator (DRAM), resulting in autophagy induction (98,102). 
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Autophagy also plays a role in DNA damage repair by providing metabolic precursors for ATP 
generation required by several DNA damage response (DDR) pathways, maintains dNTPs needed 
for DNA replication and repair, and plays a role in the turnover of key proteins involved in DDR 
and DSB processing (103). Lin et al. demonstrated that cisplatin, an alkylating agent that generates 
bulky adducts on DNA, induced autophagy through Beclin-1 activation in human bladder cancer 
(104). Similarly, Li et al. demonstrated that interference with autophagy by 3-MA or siRNA 
targeting ATG7, both in vitro and in vivo, sensitized colorectal cells to 5-fluorouracil (5-FU), a 
pyrimidine analog and antimetabolite (105). Aydinlik et al. showed autophagy induction in 
response to doxorubicin, a topoisomerase II inhibitor, in triple-negative breast cancer cells; 
furthermore, autophagy inhibition increased doxorubicin-induced cell death and increased 
sensitivity (106).  
Therapies such as radiotherapy induce excessive damage throughout the cell through direct DNA 
damaging capabilities and through the indirect generation of ROS (81,82,107,108). Both DNA 
damage and ROS are well characterized as inducers of autophagy. Ito et al. showed that radiation 
exposure in malignant glioma cell lines induced autophagy and cell cycle arrest, instead of 
apoptosis (95).  
1.3.5.2.Autophagy in response to non-DNA damaging therapy  
 
Autophagy is also induced in response to multiple chemotherapeutic modalities which are not 
considered to directly promote DNA damage. Moreover, as therapeutic approaches, such as 
targeted therapies and immunotherapy, have become an additional element of anticancer treatment 
regimens, autophagy has also been shown to be induced in response to a variety of such novel 
agents.  For example, tamoxifen and other anti-estrogens induce protective autophagy in breast 
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cancer (109). Histone deacetylase (HDAC) inhibitors, such as butyrate and SAHA, were shown to 
induce autophagy, and more specifically autophagic cell death in cervical cancer (110). The 
epidermal growth factor receptor (EGFR) represents a major target for a variety of monoclonal 
antibodies for the treatment of different cancer types. EGFR activates several downstream pro-
survival pathways, including Ras/MAPK, Jak/Stat, and PI3K/AKT/mTOR signaling pathways 
(111). While EGFR inhibitors are often effective, many cancer patients become resistant to these 
therapies; thus, further understanding of and manipulation of autophagy may serve as a potential 
therapeutic strategy for sensitization of patients to anti-EGFR therapies. In support of this 
approach, Li et al. demonstrated autophagy induction in response to cetuximab, an EGFR-blocking 
antibody, via inhibition of mTOR and activation of Beclin-1 in human vulvar squamous 
carcinoma, colorectal cancer, and NSCLC (112). Autophagy induction was further demonstrated 
in response to targeted therapy in studies where hepatocellular carcinoma (HCC) cells were shown 
to undergo autophagy in response to linifanib, a vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF) inhibitor, through suppression of PDGFR-b and its 
downstream signaling pathways, in vitro and in vivo (113).  
1.3.5.3. Non-cell autonomous effects of autophagy.  
Autophagy modulation may mediate both cell-autonomous (direct cellular) and cell non-
autonomous effects, the latter related to surrounding cells, such as immune, epithelial, and other 
tumor cells in the TME. Immune evasion by tumor cells remains a major barrier to effective cancer 
treatment. Tumor cells can develop multiple mechanisms to evade host-mediated immunity, such 
as impaired/downregulation of antigen presentation and upregulation of immune checkpoints, 
which downregulate T-cell activity (114). Yamamoto et al. demonstrated that major 
histocompatibility complex class I (MHC-I), a molecule important in antigen presentation, was 
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selectively degraded through autophagy-dependent mechanisms in pancreatic ductal 
adenocarcinoma (PDAC) cell lines (115). Furthermore, in a mouse model of PDAC tumor cells 
expressing a doxycycline-inducible dominant-negative ATG4B knockdown, autophagy inhibition 
was shown to increase MHC-1 expression and CD8+ T cell activation, enhanced T-cell mediated 
killing and consequently a reduced tumor cell viability (115). Reduced tumor burden and increase 
tumor-infiltrating T cells were also evident in a similar model with knockdown of ATG7 (115). 
Given that PDAC is refractory to immune-checkpoint blockade (ICB), the authors examined 
whether autophagy inhibition would sensitize tumors to immune-checkpoint inhibitors. Utilizing 
a syngeneic mouse model with orthotopic tumors, Yamamoto et al. demonstrated a significant 
reduction in tumor volume and increased CD8+ T cell infiltration in the ATG4B knockdown mice 
compared to autophagy-proficient mice when exposed to dual ICB (anti-PD-1 and anti-CTLA4). 
Furthermore, administration of CQ significantly sensitized tumors to the ICB therapy. Finally, 
Liang et al. also demonstrated autophagy induction in response to high-dose interleukin-2 (IL-2) 
treatment in a model of advanced metastatic murine liver tumors (116). Addition of CQ with IL-2 
therapy increased immune infiltration, reduced tumor burden, and increased survival. These data 
suggest that autophagy inhibition may be a potential strategy for the sensitization of patients to 





Figure 1.2. Autophagy induction in response to therapy.  
Anticancer therapies work through multiple mechanisms of action, such as genotoxic stress, 
oxidative stress and increase ER and mitochondrial damage. Genotoxic therapies, such as cisplatin 
and etoposide, incur DNA damage, activating DNA damage response and p53 pathways. p53 
activation can promote the transcription of autophagy-related genes (ATG’s), which contribute to 
components of the autophagic machinery. Stress, chemotherapy and radiation can also induce 
protein and organelle damage, as well as the accumulation of misfolded proteins. Excessive 
aggregation of unfolded proteins activates the unfolded protein response, UPR, in the ER, which 
promotes autophagy as a means to alleviate the burden unfolded/misfolded proteins and maintain 
homeostasis. Aside from increased ER stress, multiple chemotherapies and radiation promote the 
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generation of ROS levels as well. Increased cellular ROS levels and oxidative stress triggers HIF-
1𝑎 activation. HIF-1𝑎 can translocate into the nucleus and promote transcription of ATG genes; 
thus, inducing autophagy to prevent the accumulation of oxidative stress. Furthermore, increasing 
levels of ROS oxidize surrounding proteins resulting in oxidative damage and malfunction, as well 
as dysregulation of mitochondrial bioenergetics, exacerbating damage and activate intrinsic 
apoptotic pathways. The resulting metabolic dysfunction increases intracellular ATP, which can 
be shuttled into the extracellular space, bind to purogenic receptors on T cells, and promote 
recruitment. Autophagy has been shown to play a role in ecto-ATP release in dying cells and 
promote immune recruitment and clearance of tumor cells. Lastly, therapies, such as EGFR 
inhibitors, block tyrosine kinase receptor signaling cascades promoting mTOR activation, a known 
inhibitor of autophagy; therefore, EGFRi block upstream receptor signaling, resulting in mTOR 
inhibition and Beclin-1 activation. Taken together, autophagy is involved and induced in response 
to multiple cytotoxic therapies through a multitude of intracellular pathways as a means to prevent 
the accumulation of damage incurred by therapy. Created with BioRender.com. 
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1.3.6. Functional forms of autophagy 
While autophagy is routinely observed in tumor cells in response to chemotherapy and radiation, 
the functional contribution of autophagy to the overall outcome of therapy can vary depending on 
a number of factors, including but not limited to, the type of therapeutic utilized, time of treatment, 
dose, type of cancer and cell type. Autophagy can play multiple functions in response to 
chemotherapy and radiation treatment; however, the functional form of autophagy can only be 
determined through the impact on drug or radiation sensitivity when the autophagy is inhibited 
either pharmacologically and/or genetically. Conventional pharmacological inhibition, using 
agents such as chloroquine (CQ), Bafilomycin A1 (BafA1) or 3-methyladenine (3-MA), or genetic 
silencing techniques, including siRNA or shRNA knockdown or cell-specific gene knockout of 
Beclin-1 and essential ATG proteins, can be utilized to determine the functional form of autophagy 
induced by a particular treatment (Table 1). 
1.3.6.1.Cytoprotective Autophagy.  
One of the best-known functions of autophagy is its conventionally cytoprotective function in 
response to cellular stresses, such as serum starvation or hypoxia. In this scenario, pharmacological 
and genetic inhibition of autophagy increases sensitivity to the anticancer treatment that promotes 
autophagy (117,118). Increased sensitivity is often associated with the activation of cell death 
pathways, apparently indicating that autophagy was acting as a protective cellular mechanism for 
the evasion of cell death (119,120).  In most of the current literature, autophagy is considered to 
have a cytoprotective function; consequently, inhibition of cytoprotective autophagy would be 
anticipated to result in radiosensitization and chemosensitization. Early work performed by 
Chaachouay et al. showed that autophagy inhibition with 3-methyladenine (3-MA) and 
chloroquine (CQ) radiosensitized MDA-MB-231 (MDA-231) and HBL-100 breast cancer cells 
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(92).  Similarly, CQ was also shown to sensitize bladder cancer cells to radiotherapy both in vitro 
and in vivo and to promote apoptosis when autophagy inhibition was combined with radiation 
(121). Additionally, Qadir et al. demonstrated that autophagy inhibition sensitized MCF-7 breast 
tumor cells to tamoxifen. In these studies, sensitization was due to increased mitochondrial 
dysregulation and caspase 9-mediated apoptosis, indicating that inhibition of cytoprotective 
autophagy increased cell death (122). Similarly, Selvakumaran et al. showed that autophagy was 
induced in response to oxaliplatin in multiple colon cancer cell lines, and administration of CQ 
significantly reduced tumor volume in response to oxaliplatin and bevacizumab in HT29-derived 
orthotopic mouse tumors (123).  
A number of miRNAs have also been identified that mediate autophagy (124). The expression of 
miRNA-30a (miR-30a) is downregulated in several renal carcinoma cell (RCC) lines and patient 
samples and has been shown to inhibit autophagy through Beclin-1 downregulation. Knockdown 
of miR-30a significantly increased Beclin-1 expression and interfered with the cytotoxic effects of 
sorafenib, a multikinase inhibitor, in RCC cells (125). Pharmacological autophagy inhibition 
through CQ, 3-MA, and BafA1 reduced cell viability and increased cell death in RCC cells treated 
with sorafenib, indicating that autophagy was playing a cytoprotective function in response to 
sorafenib (125). Collectively, these studies demonstrate the functional capacity of autophagy to 
protect tumor cells challenged by anticancer therapy.  
 
Resistance  Induction of cytoprotective autophagy has also been implicated in resistance to therapy 
and can facilitate multidrug resistance (126). Utilizing epirubicin-resistant MCF-7er and SK-BR-
3er cells, Sun et al. examined the role of autophagy in multi-drug resistance (127). MCF-7er and 
SK-BR-3er cells were collaterally insensitive to paclitaxel and vinorelbine compared to parental 
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cells. Genetic silencing of Beclin-1 and ATG7 in MCF-7er and SK-BR-3er restored sensitivity to 
paclitaxel and vinorelbine. Anthracycline-resistant MDA-MB-231-R8 and SUM159PT-R75 cells 
exhibited higher basal autophagic flux than parental cells (128). Genetic knockdown of ATG5/7 
and pharmacological inhibition of autophagy with CQ or hydroxychloroquine (HCQ) significantly 
sensitized both epirubicin-sensitive and resistant triple-negative breast cancer cell lines.  These 
studies support the concept of autophagy functioning as a cytoprotective mechanism employed by 
the tumor cells to avert cell death, and that manipulation of these processes could hold therapeutic 
potential. 
Autophagy induction can also play a role in resistance by contributing to cancer stem cell 
maintenance. Cancer stem cells are a subpopulation of tumor cells that have self-renewal and 
differentiation capabilities and can contribute to resistance to anti-cancer therapy and disease 
reoccurrence (129,130). Lomonaco et al. investigated the role of autophagy in radioresistant 
glioma stem cells (GSC). CD133+ GSC cells exhibited a greater extent of autophagy when 
exposed to g-radiation compared to CD133- cells; moreover, exposure to BafA1 or genetic 
knockdown of Beclin-1 and ATG5 significantly reduced cell viability (93). These data suggest that 
autophagy is protective in response to g-radiation in CD133+ GSC cells. 
Additionally, acidic lysosomes can trap weakly basic drugs, such as doxorubicin and irinotecan, 
thereby reducing drug efficacy and conferring resistance. Guo et al. examined the role of 
autophagy in doxorubicin localization as MCF-7 cells acquired resistance to increasing doses of 
doxorubicin (131). Their studies demonstrated increased autophagy induction and sequestration of 
doxorubicin within lysosomes as MCF-7 cells developed resistance to doxorubicin treatment; 
furthermore, autophagy inhibition with CQ was sufficient to restore sensitivity in doxorubicin-
resistant MCF-7 cells.  
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While autophagy inhibition may have beneficial outcomes, in a cell-autonomous manner, the 
effects of autophagy inhibition on surrounding cells, or the cell non-autonomous aspects, must also 
be considered. Thorburn et al. demonstrated that silencing of ATG5 and ATG7 in MDA-MB-231 
TRAIL-sensitive breast tumor cells resulted in increased outgrowth of GFP-tagged TRAIL-
resistant cells when compared to autophagy-proficient controls (132). Furthermore, autophagy 
inhibition through an inducible shATG12 model in a population of GL261 glioma cells sensitive 
to EGF inhibition promoted outgrowth of GFP-tagged EGF-resistant cells. Through these studies, 
Thorburn et al. also demonstrated that autophagy inhibition in drug-sensitive cells induced caspase 
activation, and the subsequent stimulation of prostaglandin E2 (PGE2) signaling promoted tumor 
repopulation of drug-resistant cells (132,133). Taken together, autophagy inhibition may increase 
cell killing and sensitize drug-sensitive cells to therapy; however, this may promote the selection 
and growth of a resistant population, which may have detrimental therapeutic outcomes. Thus, 
there is an intricacy to autophagic function in response to chemotherapy and radiation that must 
be considered prior to the adoption of autophagy inhibition therapy. 
1.3.6.2.Cytotoxic Autophagy.  
The generally accepted premise that autophagy is cytoprotective in cells in response to stress has 
spilled over to establishing its cytoprotective function in response to anticancer therapy in tumor 
cells. Extensive preclinical data in a number of experimental tumor models and in response to 
various chemotherapeutic agents does support the cytoprotective function of autophagy based on 
the observations outlined in the previous section. However, it should be emphasized that pre-
clinical data has, in fact, demonstrated that autophagy can be divergent from this protective 
function and exhibit both a cytotoxic activity as well as, in certain cases, failing to modulate the 
tumor response to therapeutics. 
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Autophagy modulation may appear as a desirable therapeutic target; however, it is important to 
acknowledge the multi-functional nature of autophagy. In response to chemotherapy and radiation, 
cells can also undergo a cytotoxic form of autophagy, resulting in reduced cell viability and 
clonogenic survival. Cytotoxic autophagy can kill tumor cells through both apoptosis-dependent 
and independent mechanisms (117,134,135). When autophagy takes on a cytotoxic function, 
autophagy inhibition reduces tumor cell sensitivity to therapy and promotes cell viability. Studies 
by Talarico et al. examined the effects of SI113, a selective SGK1 serine/threonine inhibitor, in 
combination with radiotherapy on human glioblastoma multiforme (GM) cells (136). 
Administration of SI113 significantly reduced cell viability and oxidative stress in GM cell lines 
exposed to 5, 8, or 10 Gy of radiation. The authors demonstrated that SI113 induced autophagy 
and that the addition of CQ abolished the cytotoxicity of SI113, thus indicating that the antitumor 
effects of SI113 were mediated through induction of cytotoxic autophagy. Kanzawa et al. 
demonstrated autophagy inhibition with 3-MA and genetic silencing ameliorated temozolomide 
anti-tumor effects (137). Indeed, autophagy inhibition when the autophagy is protective in nature 
is a potential therapeutic to be exploited as a means of sensitization; however, when the autophagy 
is toxic in function, this can result in detrimental outcomes, such as tumor survival and drug 
resistance.  
1.3.6.3.Cytostatic Autophagy.  
Autophagy can also exhibit a cytostatic function in response to cancer therapeutics. Of the 
functional forms of autophagy, this is perhaps the least understood, although it is logical that cells 
exposed to stress might arrest and fail to continue to progress normally through the cell cycle.  
In the case of cytostatic autophagy, therapy-induced growth inhibition and sensitivity is mediated 
through autophagy, rather than apoptosis; furthermore, autophagy interference restores cellular 
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proliferation and ameliorates antitumor therapeutic effects (117,138). For instance, work by 
Sharma et al. demonstrated cytostatic autophagy in response to EB 1089, a vitamin D analog, in 
NSCLC cells when combined with radiation (139). The authors show that administration of EB 
1089 or 1,25-D3 significantly sensitized H460 NSCLC cells to radiation. Sensitization was not 
associated with increased DNA damage, apoptosis, or necrosis, or senescence, but rather these 
cells exhibited a more pronounced growth arrest, which was characterized as a form of cytostatic 
autophagy. Autophagy inhibition through CQ administration, shATG5 or ShBECN1 knockdown 
sensitized H460 cells to radiation alone, indicative of radiation-induced cytoprotective autophagy 
in H460 cells; however, in cells treated with EB 1089 and radiation, autophagy inhibition reversed 
the sensitization induced by EB 1089.  
Studies by Dou et al. also demonstrated cytostatic autophagy in breast cancer cells exposed to 
ivermectin, an antiparasitic drug with anticancer therapeutic potential (140). The authors showed 
that ivermectin was sufficient to suppress breast cancer cell proliferation and tumor burden, in 
vivo. Breast cancer cells were shown to undergo little or no significant apoptosis in response to 
ivermectin but did undergo autophagy. Furthermore, autophagy inhibition was sufficient to 
attenuate the antiproliferative effects of ivermectin in breast cancer cells with no significant impact 
on the extent of apoptosis, suggesting that ivermectin’s antiproliferative effects are mediated 
through induction of cytostatic autophagy (140). Whether cytostatic autophagy sensitizes tumor 
cells to therapy by contributing to the induction of quiescence or senescence is not well understood, 
and in fact, there is no literature evidence delineating the differential activation of either 
senescence or quiescence in the case of cytostatic autophagy. 
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1.3.6.4.Nonprotective Autophagy.  
A novel function of autophagy in response to therapy is the nonprotective form. In previous studies 
from our own laboratory, we identified the “non-protective” form of autophagy (141). This is a 
functional definition wherein autophagy is induced in response to radiation or chemotherapy but 
where subsequent inhibition of autophagy fails to alter radiation sensitivity (142).  Eng et al. 
demonstrated that both pharmacological inhibition of autophagy with CQ and Lys01, and genetic 
inhibition by genome editing of ATG7 did not alter sensitivity to radiation (or 30 different 
chemotherapies) of KRAS mutant tumors in vitro and in vivo. Further, they were able to show that 
CQ-mediated sensitization was independent of autophagy, suggesting the antiproliferative effects 
may be due to modulation of off-target effects (143,144). Similarly, studies performed by Schaaf 
et al. demonstrated that radiosensitization effects of CQ, 3-MA, and ATG7 deficiency were 
independent of canonical autophagy pathways and may involve effects on lysosomal degradation 
(145).  
In a seminal paper by Michaud et al, autophagy that was induced in colorectal cancer cells by 
oxaliplatin or mitoxantrone proved to be nonprotective in function, in that silencing of the 
autophagy gene, ATG7, failed to influence drug sensitivity in the tumor cells in vitro (146). 
Intriguingly, work by Cechakova et al. suggested that Lys05, an autophagy inhibitor, could 
radiosensitize H1299 (p53 null) cells, indicating a cytoprotective autophagic function in these 
NSCLC cells (147). However, a closer examination of data revealed the observed sensitization is 
modest in effect, and unlikely to be therapeutically relevant, indicating that the autophagy is likely 
acting in a nonprotective fashion. This observation serves to confirm the findings from our own 
laboratory where we reported radiation-induced nonprotective autophagy in the same H1299 (p53 
null) cells, i.e. wherein autophagy inhibition likewise failed to alter radiosensitivity (141).   
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As exemplified through the literature presented in this section, autophagy exhibits a 
multifunctional nature in response to chemotherapy and radiation. Clinical autophagy inhibition 
in scenarios where the autophagy is cytoprotective in function proves an advantageous avenue for 
chemo-and radio- sensitization. However, the capacity to determine autophagic function in 
response to antineoplastic therapy in patients is not considered or screened for prior to the addition 
of autophagy inhibitors to therapeutic regimens. This is in part due to the lack of clinical 
biomarkers or determinants of autophagic function; thus, in-depth pre-clinical studies are required 
to elucidate molecular regulators and conditions modulating the particular functions of autophagy 
before routine incorporation of autophagy inhibitors into the clinic.   
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1.3.7. p53 and autophagy 
A number of molecular pathways have been implicated in regulating autophagy; however, a 
protein that seems to be upstream of most of these regulators is p53 (19,168). p53 is a well-known 
key tumor suppressor, which is often aberrant in many tumor cell types and is frequently implicated 
in early tumorigenesis. Amongst its various cellular functions, p53 plays primary functionals role 
in regulating apoptotic cell death, cellular growth arrest, and DNA repair. While p53 has been 
shown to regulate autophagy, the nature of the relationship between p53 and autophagy is not 
completely established. Depending on spatiotemporal localization, nuclear p53 has been shown to 
activate autophagy through transcription of upstream inhibitors of mTOR and through more direct 
means, such as DRAM upregulation, which encodes a lysosomal protein inducing macroautophagy 
(102). However, on the flip side, cytoplasmic p53 protein inhibits autophagic cell death by 
inducing BECN degradation via the ubiquitin-specific peptidases USP10 and USP13 and/or 
inhibiting the AMPK-mTOR-ULK1 signaling pathway (169–171). To add further complexity to 
this relationship, autophagy can also mediate p53 turnover and degradation (159). Whether p53 
activates or suppresses autophagy is not clear; however, this may provide initial insights as to a 
potential mediator of the various functional forms of autophagy. 
Mutant p53 has also been shown to regulate autophagy to confer chemoresistance in lung cancer 
(172). Mutant p53 has been shown to upregulate Nrf2 activity, a transcription factor that codes for 
multidrug resistance, antioxidant proteins, and other proteins triggered to protect against oxidative 
and chemotoxic damage (173).  In this study, Tung et al demonstrated that wild-type p53 
suppressed Nrf2 promoter activity in NSCLC cells; however, in p53 mutant cells, promoter activity 
was not suppressed, resulting in increased mRNA levels of Nrf2 and upregulated transcription of 
the anti-apoptotic proteins, Bcl-2 and Bcl-XL, ultimately, contributing to cisplatin resistance (173). 
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Studies by Saini et al. examined the effects of p53 GOF (gain of function) mutants on cancer cell 
resistance to chemotherapy and proteasomal inhibition utilizing H1299 p53 null NSCLC cells 
transfected with either wild-type p53, R273H mutant GOF, or empty vector (174). They 
demonstrated that R273H-p53 mutant cells were significantly less sensitive to cisplatin and 5-FU 
and exhibited multi-drug resistance. While dual treatment with a proteasomal inhibitor, peptide 
aldehyde N-acetyl-leu-leu-norleucinal (ALLN), and an autophagy inhibitor did not sufficiently 
promote cell death in R273H-p53 mutant cells, activation of autophagy by serum starvation or 
rapamycin exposure promoted cytotoxic autophagy and enhanced cell killing through increased 
autophagosome accumulation and ROS levels. In contrast, Wu et al. demonstrated that cisplatin-
refractory A549 lung adenocarcinoma cells expressing wild type p53 exhibited greater basal 
autophagy compared to parental A549 cells; furthermore, treatment with cisplatin increased 
autophagy induction (175). Autophagy inhibition with CQ in cisplatin-resistant A549 cells induced 
apoptosis and resensitized these cells to cisplatin, suggesting autophagy was cytoprotective in 
function in A549 p53 wt cisplatin-refractory cells. Taken together, both NSCLC cell lines 
expressing either p53 mutant or wt p53 exhibited differential responses to cisplatin exposure, 
indicating that p53 status may impact autophagic function in response to anti-cancer therapy and 
that therapy-induced autophagy (TIA) may play a role in the development and maintenance of 
chemoresistance.  
1.3.8. Autophagy and the Immune Response 
Therapy-induced autophagy is an integral component of immunogenic cell death and immune 
modulation in response to anticancer therapy. Autophagy plays a role in the release of ATP in 
dying cells that act as chemotactic ligands for purogenic receptors on immune cells (176). This 
interaction is important in the recruitment of dendritic cells (DC) to the tumor microenvironment 
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(TME) and the subsequent activation of T cells to elicit anti-tumor responses (146,177). Studies 
by Michaud et al. demonstrated that autophagy induction in vitro did not significantly alter tumor 
cell responses to mitoxantrone (MTX) and oxaliplatin (OXA) (68). In dramatic contrast, in 
immune-competent mice, autophagy-proficient cells exhibited increased DC and T cell infiltration 
compared to autophagy-deficient cells. Autophagy inhibition suppressed ATP release and 
subsequent immune recruitment, while increasing exogenous ATP in autophagy-deficient tumors 
was able to restore immune infiltration and tumor-suppressive responses (68). These data implicate 
a role for autophagy in the release of ATP, a DAMP, and its function in eliciting anti-tumor 
immune responses to mitoxantrone or oxaliplatin in mouse colon carcinoma xenografts. Similarly, 
Ko et al. examined the immunomodulatory effects of autophagy in response to radiotherapy (176). 
These authors demonstrated that shRNA knockdown of ATG5 and Beclin-1 significantly 
radiosensitized A549 and H460 NSCLC cells and CT26 colon carcinoma cells, in vitro, and in 
immune-deficient mice. However, autophagy depletion reduced radiosensitivity and decreased 
ATP release in immune-competent mice, suggesting that autophagy-induced ATP release could 
be critical for anti-cancer immune responses (176). Consistent with the studies from Michaud et 
al., increasing exogenous ATP in autophagy-deficient tumors was able to restore immune 
infiltration and radiosensitize tumors, in vivo (176).  
Autophagy modulates immune function through multiple pathways, such as pathogen degradation, 
antigen presentation, and processing of cytokines (65,178). Autophagy can also regulate the 
trafficking of receptors to the cell surface, which are required for antigen presentation and 
complement activation (67,179).  Work by Ramakrishnan demonstrated the role of autophagy and 
tumor cell lysis by cytotoxic T lymphocytes (CTL). They showed upregulation of the mannose-6-
phosphate receptor (MPR) in tumor cells exposed to multiple therapies, including cisplatin, 
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paclitaxel and doxorubicin, as well as multiple myeloma patient tumor samples (179). 
Furthermore, MPR was implicated in chemotherapy-induced anti-CTL responses, reduced tumor 
volume, as well as cell killing of bystander tumor cells that did not express tumor antigen. 
Autophagy inhibition abrogated paclitaxel-induced MPR cell surface expression in melanoma 
cells and doxorubicin-induced MPR expression in multiple myeloma cells, as well as reducing 
CTL cytotoxicity (179), implicating autophagy in the regulation of MPR expression on tumor cell 
surfaces and CTL cell killing. Taken together, these data indicate the immunomodulatory functions 
of autophagy in both innate and adaptive immune responses to chemotherapy and radiation.   
1.3.9. Current modalities to modulate autophagy and clinical trials 
Current paradigms for clinical administration of autophagy inhibitors to sensitize patients to 
chemotherapy and radiation are based on the premise that the autophagy induced is cytoprotective 
in function; however, the clinical utilization of autophagy inhibitors has largely produced 
inconsistent results (180). Currently, the only clinically approved autophagy inhibitor is 
hydroxychloroquine (HCQ), a Food and Drug Administration (FDA)-approved anti-malarial drug 
used for prophylactic treatment of malaria, treatment for lupus or rheumatoid arthritis (181). HCQ 
acts by inhibiting lysosomal acidification, as well as preventing the fusion of the autophagosome 
to the lysosome in the final steps of autophagy (149); however, there are also off-target effects of 
HCQ, which still remain elusive (182).  
Significant pre-clinical data indicating the cytoprotective function of autophagy in response to 
chemotherapy and radiation (92,183,184) provided the foundation for the initiation of a number of 
clinical trials to inhibit autophagy as a strategy for sensitization of patients to therapy (Table 1.2). 
Studies published by Vogl et al. in 2014 examined the effects of HCQ on the efficacy of 
bortezomib, a proteasomal inhibitor, in patients with relapsed/refractory myeloma. The 
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combination of HCQ with bortezomib demonstrated partial or minor responses in 6 (28%) of 
patients and stable disease in 10 (45%) of patients (148). Furthermore, electron micrographs of 
bone marrow plasma collected from patients exhibited greater autophagic vesicles and increased 
misfolded protein trafficking with the combination therapy. Patients were given 600mg of HCQ 
twice daily with a standard dose of bortezomib and only Grade 2 gastrointestinal toxicity and 
cytopenia were observed. Similarly, studies by Barnard et al. examined the effects of HCQ 
administration in combination with doxorubicin in canine Non-Hodgkin lymphoma in a Phase I 
clinical trial. Canine patients received HCQ orally 72 h prior to standard dose of doxorubicin 
treatment. Oral HCQ administration was well tolerated with no significant grade 3 or 4 toxicities. 
Combination therapy exhibited a 93% overall response rate in canines with lymphoma, with a 
median progression-free interval of 5 months (185). In two separate studies by Levy et al., they 
were able to show improved therapeutic efficacy with autophagy inhibitors in combination with 
vemurafenib, a BRAFV600E inhibitor (186,187). Mulcahy Levy et al. examined the effects of HCQ 
administration in BRAFV600E-mutant brain tumors resistant to vemurafenib. Patients received 500 
mg CQ orally daily with continued standard dose of vemurafenib treatment. Improved therapeutic 
efficacy was exhibited in resistant patients who received CQ in combination with vemurafenib 
(186). Furthermore, increased LC3 II accumulation was seen in peripheral white blood cells in 
patients given CQ, suggesting autophagy was sufficiently inhibited. In contrast, a Phase I/II 
clinical trial combining HCQ, temozolomide (an alkylating agent), and radiation were performed 
in patients with glioblastoma multiforme (89). Doses of 600mg HCQ combined with low dose 
temozolomide failed to demonstrate improved overall survival in glioblastoma patients. 
Furthermore, when increasing doses to 800mg of HCQ daily combined with temozolomide, 
significant Grade 3 and 4 neutropenia and thrombocytopenia were exhibited.  Electron microscopic 
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images indicated increased autophagic vesicles in patients treated with radiation; however, even 
at the higher doses of HCQ, substantial autophagy inhibition could not be demonstrated.  
In addition to the dose-limiting side effects of HCQ, another limitation likely contributing to the 
inconsistent clinical results is the failure of currently available pharmacological autophagy 
inhibitors to sufficiently interfere with autophagy in patients. In order to effectively block 
autophagy in patients, significantly higher doses of HCQ would be required, which may result in 
undesirable side effects (180).  Several other clinical trials have been initiated in order to study the 
effects of autophagy inhibition on chemo- and radiosensitivity; however, these provided 
inconsistent results. HCQ as a monotherapy in patients with metastatic pancreatic adenocarcinoma 
provided inconsistent autophagy inhibition and poor therapeutic efficacy in a phase II trial (188). 
Combination of HCQ with docetaxel in patients with metastatic prostate cancer was terminated 
early due to a lack of improved efficacy (Identifier: NCT00786682).  However, several clinical 
trials have been launched utilizing higher doses of HCQ in combination with chemotherapeutics, 
such as bortexomib, which may show more promising results (148) (Identifier: NCT00568880, 
NCT01206530, NCT01506973). 
 
Table 1.2. Clinical Trials manipulating autophagy inhibition to sensitize cancer patients 
to antitumor therapy.  
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1.4.5. General Introduction and History 
Cellular senescence is a durable growth arrest induced in response to oxidative, genotoxic, 
replicative, and therapeutic stress. Senescence is originally derived from the Latin word “senex”, 
which means “old” and was first utilized by Hayflick and Morehead in the early 1960s (196,197).  
Contrary to the paradigms of the time that cells in vitro grow indefinitely, Hayflick and Morehead, 
utilizing these primary fibroblast cultures derived from embryonic tissue, discovered that cells in 
culture did not have the ability to replicate infinitely, but rather the fibroblasts replicated for a 
finite number and entered into a growth-arrested, or senescent state (196,197). Although losing 
their capacity to proliferate, these cells still remained viable and metabolically active. This was 
later described as the “Hayflick Limit”, in which telomeres, which protect chromosomal ends, 
progressively shorten during replication cycles until reaching a critical length resulting in a cease 
in cellular division (198).   
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Senescence contributes to a number of physiological processes including wound healing and 
embryonic development and has also been implicated in various aging-related diseases, 
neurological disorders, and cancer (199–201). Cellular senescence is conventionally viewed as a 
cell-autonomous tumor suppressor mechanism because it arrests and prevents the propagation of 
cells with severely mutated DNA or at risk for malignant transformation (201,202). Senescence 
cells can be identified and targeted for clearance by several elements of the immune system (203), 
adding to its anti-cancer function. However, a growing body of literature now supports the notion 
that senescence can also promote tumorigenesis, resulting in yet another cellular program 
exhibiting a double-edged sword function in cancer development (201).  Cell non-autonomous 
functions of senescent cells through secretion of the senescence-associated secretory phenotype 
(SASP) can promote the transformation of surrounding cells (204,205) and cause remodeling of 
the extracellular matrix (ECM), ultimately promoting the spread of malignant tumor cells (206–
208).  
Senescence may also present as a model of tumor dormancy (209). Damage incurred by the cells 
from radiation and chemotherapy can induce senescent growth arrest as the cell attempts to repair 
the damaged DNA. Radiation has been shown to induce a temporary period of growth arrest, 
followed by a phase of proliferative recovery (210,211) that could theoretically contribute to 
disease recurrence.  
1.4.6. Senescence and Apoptosis Evasion 
In response to chemotherapy and radiation, cancer cells can activate multiple cellular responses to 
evade apoptotic cell death. In regard to this, senescence can be induced in response to therapy as 
a mode of alternative cell fate to elude cell death, and possibly contribute to disease recurrence. 
For example, senescent cells exhibit multiple epigenetic modifications, including BCL family 
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promoters (212,213). Yosef et al demonstrated upregulation of Bcl-W and Bcl-XL expression, anti-
apoptotic proteins of the Bcl-2 protein family, in senescent human fibroblasts and showed that 
inhibition of these proteins with the pan-Bcl-2 family inhibitor, ABT-737, was sufficient to remove 
senescent cells (214). Furthermore, Saleh et al. demonstrate senescence induction in response to 
etoposide and doxorubicin in MDA-MB-231 breast cancer cells and A549 NSCLC cells, 
respectively (215). Administration of ABT-293, a Bcl-2/Bcl-XL inhibitor, increased apoptosis in 
response to doxorubicin and etoposide in MDA-MB-231 and A549 cells by interfering with Bcl-
XL interaction with BAX, a pro-apoptotic protein (215). The authors were also able to show 
sensitization to etoposide and doxorubicin, as well as reduced tumor burden in vivo, with the 
addition of ABT-263; however, ABT-263 as a monotherapy had no significant effect on tumor 
burden. These studies offer insights into the potential of senescent cells to upregulate anti-
apoptotic Bcl-2 family proteins as a means to evade apoptotic cell death and provide potential 
novel therapeutic targets for cancer treatment. 
1.4.7. Characteristics of senescence 
Senescent cells present with a myriad of phenotypes, such as morphological changes (enlargement 
and flattening), expression of a pH-dependent ß-galactosidase activity, secretion of chemokines 
and cytokines that encompass the senescence-associated secretory phenotype (SASP), and 
senescence-associated heterochromatic foci (SAHF) appearance (216–218). While senescent cells 
are growth-arrested, they maintain metabolic activity and exhibit enhanced lysosomal biogenesis 
(109,219,220). Of note, the Senescence-Associated β-galactosidase (SA-β-gal) enzyme, a 
lysosomal enzyme that functions at low lysosomal pH ~1-2 in normal cells, demonstrates an 
altered optimal pH of 6 in the lysosomes of senescent cells; moreover, this has become a key 
hallmark of senescent cells and is often utilized as the basis of multiple assays screening for 
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senescence (221). Aside from this functional change, senescent cells undergo several 
morphological and structural changes. Senescent cells appear enlarged and have flattened 
morphology due to cytoskeletal changes; moreover, some cell types may develop projections, 
appearing similar to a neuron-like shape (222,223). Cells undergoing senescence also have altered 
mitochondrial fusion and function, as well as increased mitochondrial mass and length (224). 
Cellular senescence exhibits a number of nuclear changes, including the appearance of altered 
chromatin, termed heterochromatin foci, designed to repress the expression of proliferation-related 
genes and maintain the growth-arrested state (225,226). While all of these multiple features are 
characteristics of senescence, senescent cells exhibit a heterogenous expression of these 
phenotypes and may not present all of these features; therefore, it is necessary to demonstrate 
multiple phenotypes of senescence to confirm induction.  
1.4.7.1.DNA Damage, p53, and senescence 
Senescence is a prolonged growth arrest generally associated with the induction of DNA damage 
and consequent signaling pathways. Therapy-induced DNA damage is detected by ATM, which 
phosphorylates and activates p53 (99). Activation p53 results in induction of p21Cip1 (and 
sometimes p16), inhibition of cyclin-dependent kinases, dephosphorylation of retinoblastoma 
(Rb), and the presumed formation of Rb-E2F complexes (227,228). Collectively, these responses 
interfere with the interaction between cyclin and cyclin-dependent kinases and halt cell cycle 
progression. Given that cyclin-dependent kinase inhibitors (CDKIs) can drive growth arrest, 
senescent cells often upregulate key cell cycle regulators, such as p21Cip1 and p16INK4a (229,230).  
Senescent growth arrest can furthermore be considered as an alternative cell fate that can be 
induced to allow cells to evade apoptotic cell death (231). Luo et al showed that 6 Gy radiation did 
not induce significant apoptosis in A549 and H460 cells, but rather induced a premature 
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senescence indicated by increased SA-b-gal staining. Furthermore, knockdown of p53 inhibited 
radiation-induced senescence, while restoration of p53 expression sensitized cells to radiation and 
induced senescence (232). Studies performed by Roberson et al. demonstrated induction of 
accelerated senescence in response to camptothecin, a DNA-damaging agent, in p53 null H2199 
human lung cancer cells. Of interest was that these investigators were able to show that a subset 
of cells had the capacity to escape the therapy-induced senescence and these cells resembled 
parental cells while still exhibiting SA-b-gal activity (210). 
1.4.7.2.Senescence-associated secretory phenotype 
A key characteristic of senescent cells is the SASP, which encompasses a unique secretion profile 
including cytokines, matrix metalloproteases (MMPs), growth factors, and several other soluble 
regulators (206). A number of these factors can alter the TME or promote tumor growth. 
Additionally, several of these cytokines and soluble factors participate in wound healing processes 
that modulate ECM remodeling, tissue repair, surrounding cells in the TME, as well as regulate 
immune infiltration (233). MMPs and other proteases help to remodel the ECM around tumor cells 
and can promote tumor migration (204,234). Moreover, senescent cells secrete a number of pro-
inflammatory cytokines and chemokines, such as interleukin-6 (IL-6) and interleukin-8 (IL-8), 
which can play a role in promoting tumor growth and migration. Ortiz-Montero et al demonstrated 
that when MCF-7 cells were treated with conditioned media from senescent cells, IL-6 or IL-8, 
markers of endothelial-to-mesenchymal transition (EMT) were upregulated, and promoted tumor 
cell migration and invasion (235). Both of these inflammatory factors can modulate the activation 
of the NF-kB pathway, resulting in an increase in transcription of anti-apoptotic proteins and 
promote tumor growth (236). In contrast, secretion of pro-inflammatory cytokines can promote 
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immune infiltration, and depending on the type of immune infiltrates, can promote or inhibit tumor 
growth. Studies by Meng et al utilized radiation and the PARP inhibitor, veliparib, to promote 
premature senescence in B16SIY melanoma cells (237). When these senescent cells were isolated 
and injected into C57BL/6 mice, a number of cytokines were upregulated and an increase in CD8+ 
T cell proliferation was observed in coculture studies. Furthermore, vaccination of tumor-bearing 
mice with senescent cells followed by subsequent radiation was sufficient to elicit immune 
responses and eliminate established tumors. As exemplified, cellular senescence can play a dual 
role in tumor development itself, and a verdict on whether these soluble factors produced by 
senescent cells promote or antagonize tumorigenesis has yet to be achieved (238). 
1.4.8. Senescence in response to therapy 
1.4.8.1.DNA Damaging Agents  
A number of cytotoxic cancer therapies have been shown to induce senescence in multiple different 
cancer cell types (239). Previous studies have quite conclusively demonstrated growth arrest, 
characteristic of senescence, in response to radiation therapy and DNA-damaging agents (240–
244). Cui et al showed that treatment with 4 Gy radiation in cervical cancer cells induced only 
16% apoptosis but did induce a long-lasting G2/M phase arrest (245). Cisplatin, a DNA-alkylating 
agent, was shown to induce senescence in nasopharyngeal carcinoma and ovarian cell lines 
through p53 and cdc2 induction (246,247). Etoposide, a topoisomerase II inhibitor, induced 
senescence in HepG2 hepatocarcinoma and U2OS osteosarcoma cells as exhibited by increased 
SA-ß-gal activity and p53/p21 protein levels (248). Moreover, doxorubicin, an anthracycline 
antibiotic,  mediates its anti-tumor effects by intercalating DNA base pairs, as well as inhibiting 
topoisomerase II, causing DNA strand breaks and blocking both DNA and RNA synthesis 
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(249,250). Doxorubicin has been shown to induce senescence in breast, NSCLC, colorectal cancer 
(251–254). Taken together, several chemotherapies inducing DNA damage through varying means 
seem to activate senescent programming in response to damage.  
1.4.8.2.Non-DNA damaging Agents 
While DNA-damaging agents are more often associated with senescence induction due to their 
mechanism of action, various cytotoxic cancer therapies not directly associated with causing DNA 
damage have also been shown to induce senescence (239). For example, methotrexate, an 
antimetabolite that inhibits tetrahydrofolate synthesis, was shown to activate a premature 
senescence through p53 acetylation in C85 human colon cancer cells (255). Paclitaxel is a 
microtubule poison that stabilizes tubulin and prevents its depolymerization, ultimately disrupting 
cell division (256). Exposure to paclitaxel was shown to induce senescence in bladder cancer and 
breast cancer (257,258). Furthermore, hormonal deprivation therapy, such as anti-estrogens and 
anti-androgen therapy, demonstrated senescence induction in breast and prostate cancer models, 
indicating activation of the senescent phenotype is not reliant on genotoxic stress (259–261). 
Palbociclib, a CDK4/6 inhibitor, has become a front-line treatment for advanced metastatic 
estrogen-positive breast cancer patients who developed resistance to prior anti-estrogen therapy 
(262). Palbociclib works much like a traditional CDKI, such as p21 and p16, by interfering with 
the interaction between CDK4/6 and cyclin D, resulting in a cell cycle halt (262,263). Palbociclib 
was also shown to induce both autophagy and senescence in gastric cells and breast cancer cells 
(264,265).   
While several pre-clinical models demonstrate senescence induction in response to a multitude of 
chemotherapies, radiation, and target therapies (261,265–270), activation of senescence in patient 
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tumors is poorly understood. Thus, further inquiry and advanced screening techniques are required 
to enhance our comprehension of patient tumor responses to anti-cancer therapy. 
1.4.9. Clinical Implications of Senescence: Utilization of Senolytics 
One limitation to efforts to fully understand the role and contributions of therapy-induced 
senescence in sensitivity to radiation is the absence of specific pharmacologic or genetic 
approaches to silence the senescence response. Nevertheless, our recent evidence of 
outgrowth/escape from senescence (271) argues for the likelihood that senescence, like autophagy, 
maybe a cytoprotective response that allows the tumor cells to escape elimination by radiation and 
chemotherapy. The prolonged and sustained growth inhibition may be permissive for the ultimate 
regrowth of the tumor cells and the consequent disease recurrence. Given this possibility, coupled 
with evidence that the SASP may also promote tumor growth, the recent identification of agents 
with “senolytic” properties, which promote apoptosis selectively in senescence cells opens the 
possibility of developing a therapeutic strategy for elimination of the residual surviving tumor cells 
(272,273).  
Work by Yosef and colleagues demonstrated that human fibroblasts induced into senescence by 
radiation upregulated anti-apoptotic proteins, Bcl-W and Bcl-XL in vivo. Targeting these proteins 
using a small-molecule inhibitor, ABT-737, was sufficient to eliminate these senescent cells (214). 
Similarly, Samaraweera et al. showed senescence induction and SASP secretion in both NSCLC 
cells and head and neck squamous cell carcinoma (HNSCC) cells when exposed to cisplatin or 
taxanes. Furthermore, administration of Panobinostat, an FDA-approved HDAC inhibitor, 
following chemotherapy exposure suppressed proliferation and induced cell death in both cancer 
cell types (274). While many agents have been proposed to have senolytic properties (272,275), 
not all of these compounds are universally effective; consequently, further work will be required 
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to generate clearer insights as to exactly how these agents act as “senolytics” and why particular 
agents are effective under certain experimental conditions but not others. Taken together, 
selectively targeting senescent cells while they are dormant and before they begin to regain 
proliferative recovery may serve as a therapeutic benefit and prolong patient survival, as well as 
increasing the delay before disease recurrence.  
 
In response to chemotherapy and radiation, tumor cells can undergo a number of cell fates and 
processes. While apoptosis is the desired outcome of clinical treatment, tumor cells can often 
activate various survival mechanisms, such as autophagy and senescence, in hopes to evade 
apoptotic cell death. It is, therefore, necessary to examine the contributions and function of these 
alternative cell fates on tumor cell sensitivity to anti-cancer therapy. The studies presented in this 
dissertation were designed to examine the cellular response of autophagy in radiation and cisplatin 
exposure, individually, in NSCLC cell lines, as well as the effects of p53 status on these responses. 
An additional goal was to determine whether autophagy could be modulated to sensitize tumor 




Chapter Two: What are the cellular responses and the effect of p53 
status on radiosensitivity in H460 NSCLC cells? 
2.1 Introduction 
Radiotherapy 
Radiation is an important pillar of cancer therapeutics, exerting its anti-tumor DNA-damaging 
effects through various direct and indirect mechanisms. The effects of radiation are largely 
mediated through DNA damage that is both direct and indirect, the latter via free radical generation 
(276). Thus, the efficacy of radiation is partly dependent on the oxygenation of tumors, which is 
required to generate ROS and incur damage (277). While cells respond with compensatory 
mechanisms by antioxidants, such as glutathione and superoxide dismutase (SOD), localization of 
radiation-induced damage increases ROS levels, tipping redox equilibrium, and ultimately 
resulting in cell death (278). The impact of radiation-induced damage tends to be delayed, 
occurring over several cell cycles, resulting in aberrant chromosomes and compromised DNA 
integrity. Long-term damage to normal cells/tissue at the tumor periphery remains a key issue 
when injury accumulates in critical organs. The nature of the tumor cell response to radiation can 
vary. Radiation-induced DNA strand breaks activate a multitude of DNA damage response 
processes to prevent the propagation of cells carrying the mutated/damaged DNA. Radiation has 
served as an effective mode of treatment for a number of cancer types, for both curative and 
palliative treatment; however, resistance to therapy still remains a prevalent issue. 
Although tumor cell apoptosis is the desired outcome for radiation and cytotoxic therapy, it is 
often not the sole or obligatory response to therapy. Tumor cells can activate multiple pathways, 
such as autophagy or senescence, in attempts to evade cell death pathways, which may contribute 
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to disease reoccurrence or poor patient response to therapy. Autophagy is induced as a “first 
responder”, aiding to prevent damage accumulation. Cellular stress, metabolic dysregulation, and 
oxidative stress can have detrimental effects on protein oxidative states, genome stability, and 
mitochondrial energetics (279). In order to reduce the burden of the damage, autophagy is induced 
to alleviate stress by aiding in the turnover of damaged proteins and organelles (280). While 
hypoxia- and starvation-induced autophagy represent largely cytoprotective responses (281,282), 
the role(s) of chemotherapy- and radiation-induced autophagy are less clear (117). The 
cytoprotective function of autophagy is often thought to reflect efforts by the tumor cell to prevent 
the cell from undergoing apoptosis and prolong survival (104,126). However, there are also 
extensive examples of studies where inhibition of autophagy fails to sensitize the tumor cells to 
the initiating stress (141,283,284) which we have termed “non-protective autophagy” (117,285). 
The relevance and potential clinical importance of the non-protective form of autophagy relate to 
efforts to sensitize malignancies to therapy through autophagy inhibition. That is unless the 
autophagy induced in the clinic is cytoprotective in function, there is unlikely to be a therapeutic 
advantage to its inhibition. 
Literature evidence also demonstrates the functional autophagic response is not always consistent 
in tumor cells exposed to radiotherapy (141). Further analyzing these studies by Schaaf et al., 
pharmacological inhibition with CQ and 3MA did not alter radiosensitivity in MDA-MB-231 
breast tumor cells when exposed to 5.6 Gy; however, work done by Chaachouay et al. showed 
that autophagy inhibition with similar concentrations of CQ and 3MA was sufficient to 
radiosensitize the same MDA-MB231 cell line exposed up to 5 Gy radiation (92,145). These 
contradictory observations present a conundrum within the field when the same cell line, exposed 
to similar doses of radiation and concentrations of the autophagy inhibitor, can produce two 
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divergent responses, leading to opposing conclusions relating to the role of autophagy.  Thus, the 
nature of autophagy in response to radiotherapy and mediators regulating autophagic function 
warrant further interrogation.  
Alongside autophagy, recent studies have demonstrated that radiation can also induce a cellular 
growth arrest characteristic of senescence. Senescence is an alternative cell fate that can be induced 
to allow cells to evade cell death by halting cell cycle progression (286). Radiation-induced DNA 
damage can result in a cellular senescence as the cell attempts to repair the damaged DNA; 
however, depending on the extent of damage, cells can undergo cell death if the damage is too 
great or repair the damaged DNA and allow a subset of senescent cells to regain proliferative 
capacity (287,288). p53, an essential tumor suppressor, is a central player in regulating apoptosis, 
autophagy, and senescence, and tumor cells with loss or mutated p53 have been shown to exhibit 
reduced susceptibility to radiation-induced apoptosis (289–291). Therefore, utilizing H460 p53 
wild type expressing cells (H460wt) and H460 cells with a p53 knockout generated through 
CRISPR/CAS9 technologies (H460crp53), we further examined the effects of p53 status on tumor 





2.2.1. Antibodies and reagents  
The following primary antibodies were used: SQSTM1/p62 (BD Biosciences, 610497); ATG5 
(Cell Signaling Technology, 2630); LC3B (Cell Signaling Technology, 3868); TP53 (BD 
Biosciences, 554293); GAPDH (Cell Signaling Technology, 2118). Secondary antibodies: 
Horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling, anti-mouse, 
7076S; anti-rabbit, 7074S), and TRITC-conjugated secondary antibodies (Invitrogen, A21424) 
or FITC-conjugated secondary antibodies (Invitrogen, A11070). Hoechst 33258 was purchased 
from Thermo Fisher Scientific (H3569). 
2.2.2. Cell Lines  
H460 cells were acquired from ATCC (NCI-H460). p53 knockout H460 cells were generated by 
co-transfection (3x106 cells in 10 cm dish) with 1 μg CRISPR-Cas9 plasmid targeting the p53 loci 
(Santa Cruz Biotechnologies; cat #sc-416469) and 1 μg of a homology directed repair plasmid for 
p53 (Santa Cruz, cat. #sc-416469-HDR). Cells were transfected using PolyJet reagent (Signagen) 
following the manufacturers guidelines. After 72 hours, cells were exposed to 2.5 μg/ml puromycin 
with daily media exchanges to replenish selection agent. After all cells transfected with 1 μg of a 
control CRISPR/Cas9 plasmid (Santa Cruz Biotechnologies cat#sc-418922) were killed (~96 h), 
puromycin was removed and the cells allowed to recover and grow as individual colonies, which 
were then selected and examined for expression of p53 by western blotting. 
The ATG5-knockdown was generated as follows: Mission shRNA bacterial stocks for ATG5 
were purchased from Sigma Aldrich. Lentiviruses were produced in HEK 293T cells co-
transfected using EndoFectinTM Lenti Transfection Reagent (GeneCopoeia, 1001-01) with a 
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packaging mixture of psPAX2 and pMD2.G constructs (Addgene). Media containing the viruses 
was used to infect the H460 cells; puromycin (1 μg/ml) was used as a selection marker to enrich 
for the infected cells.  
2.2.3. Cell Culture and Treatment 
H460wt and H460crp53 NSCLC cells were cultured in DMEM media supplemented with 10% 
(v/v) fetal bovine serum (Thermo Scientific), 100 U/ml penicillin G sodium (Invitrogen), and 100 
μg/ml streptomycin sulfate (Invitrogen). Puromycin (1 μg/ml; Sigma) was used to maintain the 
selection of shATG5 and shControl transfected cells. Cells were incubated at 37℃ under 
humidified 5% CO2. 
Cells were seeded on day 0 followed by irradiation (0,2,4,6, or 8 Gy) on day 1 utilizing a 137Cs 
irradiator. Media was replenished every other day.  
2.2.4. Cell Viability Assay 
For cell viability assessed by trypan blue exclusion, cells were plated in 6-well plates at a density 
of 50,000 cells per well and pre-treated with 3MA (0 or 1 mM), CQ (0 or 10 µM), or Baf A1 (0 or 
5 nM) 3 h prior to irradiation (0,2,4,6, or 8 Gy). Media was replenished 24 h post-radiation. Cells 
were trypsinized, stained with 0.4% trypan blue (Sigma, T01282), and counted on the indicated 
days using a hemocytometer.  Cellular growth curves were generated from the collected data.  
2.2.5. Assessment of Apoptosis 
The extent of apoptosis was monitored by Annexin V-FITC and Propidium Iodide staining. Cells 
were pre-treated with 3MA (0 or 1 mM), CQ (0 or 10 µM), or Baf A1 (0 or 5 nM) 3 h prior to 
irradiation (0,2,4,6, or 8 Gy). Media was replenished 24 h post-radiation. On the day of analysis, 
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cells were trypsinized, washed with 1X PBS and stained according to manufacturer protocol 
(Annexin V-FITC Apoptosis Detection Kit; BD Biosciences, 556547). Fluorescence was 
measured using flow cytometry using BD FACSCanto II and BD FACSDiva software at the Flow 
Cytometry Core Facility at Virginia Commonwealth University. For all flow cytometry 
experiments, 10,000 cells per replicate were analyzed and three replicates for each condition were 
analyzed per independent experiment. 
2.2.6. Determination of Acidic Vesicle formation through Acridine Orange Staining 
Cells were plated in 6-well plates at a density of 50,000 cells per well and pre-treated with 3MA 
(0 or 1 mM), CQ (0 or 10 µM), or Baf A1 (0 or 5 nM) 3 h prior to irradiation (0,2,4,6, or 8 Gy). 
Media was replenished 24 h post-radiation. Cells were stained with 1 μg/ml acridine orange at 37
℃ for 15 min and then washed with PBS. Cells were imaged using an inverted fluorescence 
microscope (Olympus, Tokyo, Japan). For quantification of autophagic vesicles (AVOs), cells 
were trypsinized, harvested and washed with PBS. Pellet fractions were resuspended in PBS and 
analyzed by BD FACSCanto II and BD FACSDiva software. All experimental procedures were 
performed with cells protected from light. 
2.2.7. LC3/LAMP2 Co-localization 
For immunofluorescence staining, cells were treated with 6 Gy radiation and staining was 
performed 72 h post-radiation. Cells were fixed with 100% methanol for 15 min, permeabilized 
with 0.1% Triton X-100 for 15 min, and then blocked with 5% bovine serum albumin (BSA). 
Cells were incubated with primary antibody (1:100) overnight at 4°C, and then exposed to FITC- 
or TRITC-conjugated secondary antibody for 2 h at room temperature. Finally, nuclei were 
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stained by Hoechst 33258. Immunofluorescence was detected by inverted fluorescence 
microscopy (Olympus, Tokyo, Japan). 
2.2.8. Western Blot Analysis 
After indicated treatments, cells were trypsinized, harvested, and washed with 1X PBS. Pellets 
were lysed with CHAPS buffer (Thermo Scientific) containing protease inhibitor (Sigma, P8340) 
and phosphatase inhibitor Sigma, P576). Protein concentrations were determined by the Bradford 
Assay (Bio-Rad Laboratories, 5000205 Total protein was diluted in sample buffer and boiled for 
15 minutes prior to loading. Protein samples were loaded and subjected to SDS-polyacrylamide 
gel electrophoresis, transferred to polyvinylidene difluoride membrane, and blocked with 5% 
milk in 1X PBS with 0.1% Tween 20 (Fisher, BP337). Membrane was incubated overnight at 
4°C with indicated primary antibodies at a dilution of 1:1000 in 5% BSA. The membrane was 
then washed with 1X PBS with 0.1% Tween 20 three times and secondary antibody was added at 
a dilution of 1:2000 in 5% BSA for 2 h at room temperature. The membrane was washed again 
with 1X PBS with 0.1% Tween 20 three times. Blots were developed using Pierce enhanced 
chemiluminescence reagents (Thermo Scientific, 32132) on BioRad ChemiDoc System. 
Densitometry analysis of the western blots was performed using NIH software Image J2. Except 
in the case of LC3, all protein band densities were normalized for their corresponding GAPDH 
loading control band densities. 
2.2.9. β-galactosidase and C12FDG staining  
Cells were plated in 6-well plates at a density of 50,000 cells per well and treated with irradiation 
(0,2,4,6, or 8 Gy). Media was replenished 24 h post-radiation. β-galactosidase staining was 
utilized to qualitatively visualize senescent cells. Staining was performed as previously described 
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by Dimri et al. (292). Phase contrast images were taken using an inverted microscope (Olympus, 
Tokyo, Japan). 
To quantify ß-gal positive senescent cells, after irradiation, cells were treated with Bafilomycin 
A1 (100 nM) for 1 h to achieve lysosomal alkalinization, followed by staining with C12FDG (10 
μM) for 2 h at 37 ℃. After incubation, cells were collected and analyzed by BD FACSCanto II 
and BD FACSDiva software. All experimental procedures were performed with cells protected 
from light. 
2.2.10. Extent of DNA Damage  
Cells were seeded in 6-well plates and incubated overnight. After exposure to the indicated treatment, cells 
were fixed with 70% ethanol for 15 minutes and then blocked with 5% bovine serum albumin (BSA). Cells 
were incubated with gH2AX antibody (1:1000; BD Pharmagen, 560445) for 2 h, and fluorescence was 
quantified using flow cytometry. For quantification of DNA damage, cells were trypsinized, harvested and 
washed with PBS. Pellet fractions were resuspended in PBS and analyzed by BD FACSCanto II and BD 
FACSDiva software. All experimental procedures were performed with cells protected from light. 
2.2.11. Statistical analysis  
GraphPad Prism 5.0 software was utilized to conduct statistical analysis. Data are shown as mean 
± SD from at least three separate experiments, unless indicated otherwise. Statistical comparisons 
between groups were assessed via one-way ANOVA followed by Bonferroni post-hoc test and 
two-tailed t tests; p-value < 0.05 was considered statistically significant. 
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2.3. Results 
2.3.1. Radiation Sensitivity in p53 Wild-type and p53 Knockout H460 cells 
Mutations to p53 or loss of p53, an essential tumor suppressor gene, have been reported in more 
than 50% of tumor cell types, including lung, breast, colon, and many others (16,293). The status 
of p53 and its contributions to radiation sensitivity has become an area of important interest over 
the years; however, the mechanisms underlying the effect of p53 status on radiosensitivity and 
resistance to therapy still remains elusive. To further interrogate this question, we utilized p53 
wild-type H460 NSCLC cells and H460 cells with a p53 knockout generated through 
CRISPR/CAS9 gene-editing (Figure 2.1A). Radiation sensitivity was assessed in both cell lines 
through analysis of cell viability over time using trypan blue exclusion. Temporal analysis of 
radiosensitivity demonstrated that H460wt cells were significantly more sensitive than H460crp53 
cells (Figure 2.1B). Furthermore, H460wt cells exhibited growth arrest in response to 6 Gy 











Figure 2.1. Sensitivity to ionizing radiation (IR) in H460wt and H460crp53 NSCLC cells.  
A. Western blot analysis. B. Temporal analysis of cell viability. Cells were exposed to 6 Gy 
radiation, incubated with fresh medium for the indicated number of days and viable cell number 
determined by trypan blue exclusion. Results were from three independent experiments. *p < 0.05, 
radiation exposure in H460wt cells versus H460crp53 cells.   
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2.3.2. Radiation induced apoptosis in H460wt and H460crp53 cells.  
In response to radiotherapy, H460wt and H460crp53 cells exhibited differential sensitivity. 
Previous literature has suggested loss of functional p53 can reduce cellular susceptibility to 
apoptotic cell death (291,294). To further inquire whether the differences in sensitivity were a 
result of cell death, we examined the extent of apoptosis induced in response to radiation in both 
of these cell lines.  Cells were exposed to varying doses of radiation and the extent of apoptosis 
was measured through Annexin V/PI staining. The fluorescence was quantified using flow 
cytometry. Figure 2.2A demonstrates the extent of apoptosis in both cell lines was relatively low 
and induced to similar extents in both H460wt and H460crp53 cells in a dose-response study of 
radiation-induced apoptosis. Further examining the induction of apoptosis over time, cells were 
exposed to 6 Gy radiation and radiation-induced apoptosis was assessed on the indicated days. 
Radiation did moderately increase apoptotic cell death, falling in between ~15-25% with 72 h post-
radiation exposure; however, consistent with the dose-response study, the extent of apoptosis was 
similar in both H460wt and H460crp53 cells (Figure 2.2B). Taken together, these data indicate, 
the differential sensitivity exhibited between H460wt and H460crp53 cells was not a result of 
















Figure 2.2. Radiation induced apoptosis in H460wt and H460crp53 cells to a similar extent. 
A. Apoptosis Dose Response. After exposure to the indicated doses of radiation, cells were 
incubated with fresh medium for 2 days, and apoptotic cells identified by Annexin V/PI staining 
and flow cytometry. B. Apoptosis Time Course. After exposure to 6 Gy radiation, apoptotic 
cells were identified by Annexin V/PI staining and flow cytometry at the indicated days. Results 
were from three independent experiments. *p < 0.05, radiation exposure in H460wt cells versus 
H460crp53 cells.   
  




































2.3.3. Radiation induced autophagy in both H460wt and H460crp53 cell 
Extensive literature evidence indicates that autophagy is often induced in response to radiation-
induced damage (91,92). Consequently, we examined autophagy induction in response to radiation 
exposure in both cell lines, utilizing acridine orange to demonstrate acidic vesicle formation as an 
initial screen. While acridine orange is not a specific indicator of early autophagosome formation, 
it can be utilized as an indication for later stages of autophagy, as the autophagosome fuses with 
lysosomes to form acidic vacuoles termed “autolysosomes” (295).  An increase in acidic vacuole 
formation was demonstrated 72 h post-6 Gy radiation exposure in both H460wt and H460crp53 
cells (Figure 2.3A). A dose-response in acridine orange fluorescence was further quantified using 
flow cytometry. Dose-dependent acidic vesicle formation was exhibited in both H460wt and 
H460crp53 cells 72 h post-radiation exposure; however, acridine orange fluorescence was greater 
in H460wt cells compared to H460crp53 cells (Figure 2.3B). To further confirm autophagy 
induction, western blot analysis was utilized to determine lipidation of LC3 (LC3 I to LC3 II 
conversion) and degradation of p62/SQSTM1 protein levels. Figure 3C demonstrates autophagic 
induction and autophagic flux (i.e., autophagy going to completion) in both cell lines, as indicated 
by LC3 I-II conversion and p62 protein degradation in both H460wt and H460crp53 cells exposed 
to 6 Gy radiation. Interestingly, p62 degradation occurs on Day 4 in H460crp53 cells compared to 
H460wt cells where significant p62 degradation is evident on Day 1, suggesting that autophagy 
may be delayed in H460crp53 cells. The difference in the rate of autophagic flux between the two 
cell lines may contribute to differences seen in the acridine orange quantification since the acridine 
orange studies were performed on Day 3. Finally, Figure 2.3C demonstrates co-localization of 
LC3 (green), an autophagosome marker, to LAMP-2 (red), a lysosomal marker, indicating fusion 
(yellow) of autophagosomes with lysosomes in the final steps of autophagy completion. In 
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response to 6 Gy radiation exposure, both H460wt and H460crp53 cells exhibited increased LC3 
(green) fluorescence, indicating autophagy induction. Furthermore, merging of LC3 and LAMP-2 
demonstrated the formation of autolysosomes (yellow) in both H460wt and H460crp53 cells 72 h 
post-IR exposure, indicating autophagy was going to completion. Interestingly, untreated 
H460crp53 exhibited higher LC3 immunofluorescence compared to H460wt cells, suggesting 
basal autophagy was higher in H460crp53 cells compared to their p53 wt counterpart. Collectively, 
these data indicate autophagy was induced and autophagic flux was occurring in response IR 
exposure in both H460wt and H460crp53 cells, and autophagic that flux is delayed in H460crp53 






Figure 2.3. Radiation-induced autophagy in H460wt and H460crpp53 NSCLC cells.  
A. Acridine orange staining. Three days after exposure to 6 Gy radiation, cells were stained 
with acridine orange; images were taken at the identical magnification (scale bar = 200 μm, n = 
2). B. Quantification of acridine orange staining. Autophagy was quantified based on acridine 
orange staining as measured by flow cytometry. C. Western blotting for levels of relevant 
proteins. The status of p53 in both H460 cell lines was confirmed by western blotting. Autophagy 
was assessed based on p62/SQSTM1 degradation and the conversion of LC3 I to LC3 II. The bar 
graph in each panel indicates the relative band intensity generated from densitometric scans of 
three independent experiments in arbitrary densitometric units. D. Co-localization of LC3 and 
LAMP. Fluorescence microscopy showing LC3 and LAMP2 co-localization in response to 6 Gy 
radiation. Imaging was performed 3 days after radiation exposure (scale bar = 20 μm, n = 2). 
Unless stated, otherwise data were from three independent experiments. *p < 0.05, control cells 




2.3.4. Nonprotective autophagy induced in response to radiotherapy in H460wt and 
H460crp53 cells 
In response to chemotherapy and radiation, autophagy is often thought to elicit its conventional 
cytoprotective function in order to remove damaged organelles and proteins and prevent toxic 
accumulation (296,297). While autophagy can play a cytoprotective function in response to anti-
cancer therapy, autophagy can also be multifunctional in its role. Therefore, we interrogated the 
functional role of autophagy in response to radiotherapy to identify whether functional differences 
in autophagy contributed to the differential radiosensitivity exhibited between H460wt and 
H460crp53 cells. The pharmacological autophagy inhibitor, 3-methyadenine (3-MA), was utilized 
to examine the effects of autophagy inhibition on radiosensitivity of these two isogenic cell lines. 
3-MA is a class III PI3K inhibitor, which is essential for induction and initiation of autophagosome 
formation (153). To ensure autophagy was sufficiently inhibited, acridine orange staining and 
western blot analysis was utilized. Cells were pre-treated with 3-MA (1 mM) for 3 h followed by 
6 Gy IR and stained with acridine orange or protein lysates were collected 72 h post-radiation for 
Western blotting. Figure 2.4A demonstrated reduced acidic vacuoles when cells were exposed to 
3-MA prior to IR treatment in both H460 and H460crp53 cells. Furthermore, autophagy inhibition 
with 3-MA was confirmed through western blot analysis. Figure 2.4B shows that administration 
of 3-MA in H460wt and H460crp53 cells resulted in a reduced LC3 II/I conversion ratio, 
suggesting 3-MA in combination with radiation was sufficient to inhibit autophagy in both cell 
lines. Next, the effects of pharmacological inhibition of autophagy on radiosensitivity in H460wt 
and H460crp53 cells were examined. Cells were pre-treated with 3-MA (1 mM) for 3 h followed 
by 6 Gy radiation. Autophagy inhibition through 3-MA exposure prior to 6 Gy IR did not 
significantly alter sensitivity to radiation when examining cell viability over time in both of these 
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cell lines and did not interfere with radiation-induced cell death (Figure 2.4C-D). Taken together, 
pharmacological autophagy inhibition did not significantly alter radiosensitivity or radiation-
induced cell death in H460wt and H460crp53 cells, indicating that autophagy was nonprotective 







Figure 2.4. 3-MA fails to alter radiation sensitivity in H460wt or H460crp53 NSCLC cells. 
A. Inhibition of autophagy by 3-MA. Western blot showing autophagy blockade by 3-MA (1 
mM) based on levels of LC3 II. Cells were pretreated with 3-MA for 3 h prior to radiation and 
protein was collected three days after irradiation. The bar graph in each panel indicates the relative 
band intensity generated from densitometric scans of two independent experiments in arbitrary 
densitometric units. B. Inhibition of autophagy by 3-MA. Cells were pretreated with 3-MA for 
3 h prior to radiation and cells were stained with acridine orange three days after irradiation (scale 
bar = 200 μm, n = 2). C. Influence of 3-MA on radiation sensitivity. Cell viability assay 
indicating that 3-MA has no effect on radiosensitivity in either H460wt or H460crp53 cells. Cells 
were pretreated with 3-MA for 3 h followed by radiation. D. Influence of 3-MA on radiation 
induced apoptosis. Annexin V/PI staining showing that 3-MA has no effect on radiation induced 
apoptosis in either cell line. Cells were pretreated with 3-MA for 3 h prior to radiation and 
apoptosis was assessed after 2 post-treatment. Unless stated, otherwise data were from three 




CQ is a late-stage autophagy inhibitor, which accumulates within lysosomes and increases 
lysosomal pH and prevents fusion of the autophagosome to the lysosome (149). Figure 2.5A 
demonstrated lysosomal alkalization (yellow puncta in basic conditions rather than orange/red 
puncta in acidic conditions) when cells were exposed to CQ prior to IR treatment in both H460 
and H460crp53 cells. Furthermore, autophagy inhibition with CQ was confirmed through western 
blot analysis. Figure 2.5B shows administration of CQ in H460wt and H460crp53 cells resulted 
in an increase accumulation of LC3 II/I ratio and prevented p62 protein degradation, suggesting 
CQ in combination with radiation was sufficient to inhibit autophagic flux in both cell lines. Next, 
the effects of pharmacological inhibition of autophagy on radiosensitivity in H460wt and 
H460crp53 cells were examined. Cells were pre-treated with CQ (10 µM) for 3 h followed by 
varying doses of radiation, colonies were allowed to form, and the number of colonies were 
counted. Figure 2.5C shows that CQ sensitized the H460wt cells to radiation while failing to 
influence radiation sensitivity in the H460crp53 cells. Figure 2.5D presents a temporal analysis 
of cell viability in both cell lines, confirming that the combination of 6 Gy radiation and CQ 
enhanced growth inhibition in the H460wt cells, but not in the H460crp53 cells. Furthermore, 
annexin V/PI staining showed that CQ significantly (but modestly) increased radiation-induced 
apoptosis (from ~ 24% to 37%) in the H460wt cells but did not alter apoptosis in the H460crp53 
cells (Figure 2.5E). Taken together, CQ inhibition of radiation-induced autophagy suggests that 
autophagy provides a modest (albeit statistically significant) survival advantage to cells with 
functional p53, which is however inconsistent with the more pronounced radiation sensitivity 










Figure 2.5. Influence of chloroquine (CQ) on radiation sensitivity in H460wt and H460crp53 
cells.  
A. Inhibition of autophagy by CQ. Fluorescence microscopy showing acridine orange-stained 
vacuoles induced by 6 Gy radiation alone or with CQ (10 μM) treatment (scale bar = 200 μm). B. 
Inhibition of autophagy by CQ. Western blot showing autophagy blockade by CQ (10 μM) based 
on levels of p62/SQSTMQ and LC3 II. Cells were pretreated with CQ for 3 h prior to irradiation 
and protein was isolated after 3 days. The bar graph in each panel indicates the relative band 
intensity generated from densitometric scans of three independent experiments in arbitrary 
densitometric units. C. Influence of autophagy inhibition on radiation sensitivity. Cell viability 
assay indicating that CQ increased sensitivity of H460wt cells to radiation (6 Gy), but not 
H460crp53 cells. D. Influence of autophagy inhibition on radiation induced apoptosis. 
Annexin V/PI staining indicating that CQ (10 μM) increased radiation-induced apoptosis (after 2 
days) in H460wt cells, but not in H460crp53 cells. Results were from three independent 




Further, these data conflicted with the findings of the early-stage pharmacological inhibition data 
in H460wt cells, which demonstrated lack of radiosensitization in both H460wt and H460crp53 
cells when 3MA was administered. One possibility to the differences exhibited in autophagic 
function in H460wt cells is that the autophagy was not actually cytoprotective and that the 
sensitization observed in the H460wt cells might have been due to off-target effects of the 
chloroquine, as has been proposed by the Thorburn laboratories (298). Finally, to confirm these 
findings when late stage autophagy is inhibited, we used bafilomycin A1, which disrupts 
autophagic flux by inhibiting V-ATPase-dependent decrease in lysosomal pH and, thus, 
autophagosome-lysosome fusion (150). Bafilomycin A1 interfered with the completion of 
radiation-induced autophagy in H460wt cells based on failure of lysosomal acidification (Figure 
2.6A) and upon p62 accumulation (Figure 2.6B). Again, in agreement with the previous 
observations, bafilomycin A1 had no impact on radiation-induced growth inhibition (Figure 
2.6C). These results further confirm that CQ effect in H460wt was likely non-specific, that late-
stage autophagy inhibition does not interfere with radiation sensitivity in this cell model, and that 









Figure 2.6. Influence of Bafilomycin A1 (Baf A1) on radiation sensitivity in H460wt cells.  
A. Inhibition of autophagy by Baf A1. Fluorescence microscopy showing acridine orange-
stained vacuoles induced by 6 Gy radiation alone or with Baf A1 (5 nM) treatment (scale bar = 
200 μm).  B. Inhibition of autophagy by Baf A1. Western blot showing autophagy blockade by 
Baf A1 (5 nM) based on levels of p62/SQSTMQ (n=2). Cells were pretreated with Baf A1 for 3 h 
prior to irradiation and protein was isolated after 3 days. C. Influence of autophagy inhibition 
on radiation sensitivity. Cells were pretreated with Baf A1 for 3 h followed by radiation. Cell 
viability assay indicating that Baf A1 has no effect on radiosensitivity in H460wt cells. 
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To further confirm these results, short hairpin RNA was used to knock down ATG5, an autophagy-
related gene important in proper autophagosome formation (295), in both cell lines.  Figure 2.7A 
demonstrates reduced ATG5-ATG12 complex protein levels in both H460wt and H460crp53 cells 
where ATG5 was knocked down (shATG5 cells) compared to scrambled controls (shControl 
cells). Moreover, shATG5 cells exposed to radiation in both the H460wt and H460crp53 cells 
exhibited increased p62 accumulation and reduced LC3 I to II conversion compared to shControl 
cells treated with 6 Gy IR, confirming that autophagy had been suppressed in both cell lines. Next, 
radiosensitivity was examined in autophagy-competent and autophagy-deficient H460wt and 
H460crp53 cell lines. Figure 2.7B show autophagy-deficient H460wt and H460crp53 cells did not 
demonstrate altered radiosensitivity in comparison to autophagy-proficient controls when 
assessing cell viability over time. Lastly, autophagy inhibition did not interfere with radiation-
induced apoptosis in both cell lines (Figure 2.7C). Collectively, pharmacological and genetic 
inhibition of autophagy did not alter radiosensitivity or radiation-induced cell death in H460wt and 
H460crp53 cells, indicating that autophagy was nonprotective in function in both of these cell 
lines. Given that autophagy was nonprotective in both H460wt and H460crp53 cells, these data 
suggested that differences in autophagic function was unlikely to contribute to the differential 








Figure 2.7. Atg5 knockdown fails to alter radiation sensitivity in H460wt and H460crp53 
cells.  
A. ATG5 knockdown. Cells were collected three days after irradiation. Western blot showing 
ATG5 knockdown in H460wt and H460crp53 cell lines; inhibition of autophagy in shAtg5 
H460wt and H460crp53 cell lines is indicated by reduced conversion of LC3I to LC3II and 
interference with degradation of p62/SQSTM1. The bar graph in each panel indicates the relative 
band intensity generated from densitometric scans of two independent experiments in arbitrary 
densitometric units. B. Lack of radiation sensitization by autophagy inhibition. Temporal 
viability assay indicating that Atg5 knockdown has no effect on radiosensitivity in either H460wt 
or H460crp53 cells. Cells were treated with 6 Gy radiation. C. Autophagy inhibition does not 
increase the extent of radiation-induced apoptosis Annexin V/PI staining indicating that 
apoptosis induced by radiation was unaltered after Atg5 knockdown in both H460wt and 
H460crp53 cell lines.  Unless stated, otherwise data were from three independent experiments. 




2.3.5. Radiation induced senescence in H460wt and H460crp53 cells  
Tumor cells can activate a plethora of cellular processes when exposed to chemotherapy and 
radiation. p53 plays a central role in modulating various cellular responses under stressed 
conditions, including autophagy and senescence. Previous literature has demonstrated that 
autophagy and senescence are primary responses to radiation (91,183,299,300) and often occur in 
parallel. Thus, we aimed to investigate the role of senescence induction and its contributions to the 
differential sensitivity seen between H460wt and H460crp53 cells. Cells were exposed to 6 Gy 
radiation and senescence-associated ß-galactosidase (SA-ß-gal) activity was assayed 72 h post-
radiation. Figure 2.8A demonstrates ß-galactosidase staining (blue) was qualitatively greater in 
the H460wt cells compared to H460crp53 cells; furthermore, H460wt cells visually exhibited more 
pronounced evidence of an enlarged, flatten morphology compared to H460crp53 cells.  SA-ß-gal 
activity was also monitored by flow cytometry for a more quantitative approach. SA-ß-gal was 
increased in both cell lines; however, SA-ß-gal staining was significantly greater in H460wt cells 
over time when compared to H460crp53 cells (Figure 2.8B). These data indicate the extent of 
senescence induction was greater in H460wt cells compared to H460crp53 cells and suggested that 
the differential extent of senescence induction likely was the critical factor accounting for the 
differences in radiosensitivity exhibited by the two cell lines. Given limitations in the field, 
specifically, the lack of availability of a specific senescence inhibitor, the precise contributions of 
senescence induction towards radiosensitivity remains unclear and will require further inquiry as 










      
 
 
Figure 2.8. Radiation induced senescence in H460wt and H460crp53 cells.  
A. β-galactosidase staining and cell morphology. β-galactosidase staining indicating the 
induction of senescence by radiation (6 Gy) in both cell lines (scale bar = 20 μm). B. 
Quantification of senescence. C12FDG staining and flow cytometry to quantify the extent of 
senescence in H460wt and H460crp53 cells. H460wt cells exhibited greater induction of 
senescence than H460crp53 cells. Unless stated, otherwise data were from three independent 
experiments. *p < 0.05, control vs radiation treated group.  
  






















Ionizing radiation triggers a spectrum of responses in tumor cells including apoptosis, necrosis, 
autophagy, and senescence (301–303); however, it is not yet clear what role each of these 
responses may play in tumor cell radiation sensitivity or resistance and whether the responses are 
tumor-specific. 
While irradiated tumor cells clearly do undergo apoptotic cell death, the extent of apoptosis tends 
to be relatively low (304–306). Clinically relevant or even significantly higher doses of radiation 
induced only~ 20-30% apoptosis in several experimental tumor cell lines, including breast cancer, 
non-small cell lung cancer (NSCLC), and colorectal cancer (141). For instance, Rodel et al. 
demonstrated relative levels of apoptosis between 12% and 27% induced in response to 8 Gy 
radiation in colorectal cell lines with varying radiosensitivity (306). Similarly, Qu et al reported 
~20-25% apoptotic induction in MCF-7 breast cancer cells and A549 lung cancer cells with 8 Gy 
radiation (307). In agreement with these data, previous work performed in our laboratory 
demonstrated low levels of apoptosis (~20%) induced in breast, lung, colorectal, and head and 
neck cell lines when exposed to fractionated radiation (141). It is only when higher levels of 
radiation are reached (above 10 Gy) that apoptosis becomes a more pronounced response to 
radiotherapy (308). This is, of course, relevant to stereotactic radiation, wherein patients are 
delivered multiple precisely focused beams of fractionated radiation to achieve higher effective 
doses to the tumor while minimizing damage to surrounding tissue (309–311). With regard to 
cancer treatment modalities, apoptosis or other forms of cell death are, of necessity, the desired 
outcomes; however, there a number of survival mechanisms cancer cells have employed to evade 
(apoptotic) cell death. Both autophagy and senescence can allow cancer cells to mitigate or perhaps 
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delay the damage incurred by clinical therapeutic modalities, escape cell death, and prolong 
survival. 
Resistance to therapy is a primary reason for poor prognosis and treatment failure in cancer 
patients. Drug resistance in tumor cells can involve multiple mechanisms, including physical 
barriers, lysosomal trapping of weak bases, and upregulation of several survival pathways. 
Autophagy is often a “first responder” in times of cellular stress and activated in response to 
cytotoxic insult. Cytoprotective autophagy has been implicated in tumor cell resistance to therapy, 
as it prevents the accumulation of toxic damage. Through modulation of ROS levels and removal 
of radiation-induced damage, cytoprotective autophagy can also contribute to radioresistance. 
Studies by Chen et al. showed that low-dose ionizing radiation after high-dose radiation increased 
ROS levels, autophagy induction and promoted radioresistance in A549 NSCLC cells (312). 
Subsequent autophagy inhibition reduced cell viability of A549 cells in response to radiotherapy, 
suggesting that autophagy was functionally protective in this experimental model. Moreover, 
administration of N-acetyl-L-cysteine (NAC), a known free radical scavenger, blocked autophagy 
and was sufficient to suppress the induced radioresistance. These studies indicate that high levels 
of ROS can promote cytoprotective autophagy in lung cancer cells and thereby contribute to 
radioresistance. Ko et al also demonstrated that genetic inhibition of autophagy radiosensitizes 
H460 and A549 cells in vitro; however, when moved to an in vivo model of immune-competent 
mice, autophagy inhibition reduced responses to radiotherapy, indicating that autophagy may be 
necessary for immune clearance of tumor cells in response to radiation (176). In contrast, 
Kuwahara et al. utilized radioresistant liver cancer cell lines, which they had previously generated, 
to better understand the contributions of autophagy towards radioresistance (313). These 
investigators demonstrated autophagy induction in response to radiotherapy in both the parental 
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HepG2 cells and in the resistant cells (HepG2-8960-R). Furthermore, exposure to rapamycin, an 
mTOR inhibitor and autophagy inducer, sensitized HepG2-8960-R cells to radiation (10 Gy) but 
not the parental cell line. Pharmacological and genetic inhibition of autophagy reduced rather than 
increasing sensitivity to acute radiation exposure (2 Gy), suggesting that suppression of cytotoxic 
autophagy could contribute to radioresistance.  However, there is relatively limited literature 
relating to the role of autophagy in acquired radiation resistance. These observations add another 
layer of intricacy to the overall role and contributions of autophagy to tumor cell growth and host 
immune cell modulation.   
Due to its conventionally cytoprotective function, autophagy has been implicated in tumor cell 
resistance to therapy (119), making it an attractive target to sensitize tumor cells to anti-cancer 
therapy. However, in addition to the cytoprotective form of autophagy, there is accumulating 
evidence suggesting that autophagy can contribute to or mediate drug cytotoxicity (136,313), as 
well as function in a non-protective role, wherein autophagy inhibition would not alter 
chemosensitivity or radiosensitivity (117). Early studies by the Rodemann group as well as others 
identified cytoprotective autophagy in response to radiation in a number of experimental tumor 
cell models (92,183). In comparison, we have previously identified the nonprotective function of 
autophagy in tumor cells exposed to radiation (118,141) while other laboratories have 
demonstrated nonprotective autophagy in response to chemotherapy (143). 
In the current work, we attempted to address this question by using our models of radiation-induced 
cytoprotective and non-protective autophagy to compare radiation sensitivity, based on the 
premise that tumor cells in which autophagy is cytoprotective would be expected to be significantly 
less sensitive to radiation than tumor cells in which the autophagy did not exhibit the cytoprotective 
function. Unexpectedly, only CQ treatment increased the radiosensitivity of the H460wt cells, 
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whereas 3-MA, bafilomycin A1 and genetic autophagy inhibition showed no effect on 
radiosensitivity in either cell line, raising further reservations as to the utilization of chloroquine 
as an autophagic inhibitor in the experimental discernment of the nature of autophagy. This finding 
supports the studies by Maycotte et al. that suggested chemosensitization by CQ could occur 
independently of autophagy inhibition (298). Qu et al. demonstrated CQ administration, but not 
3-MA exposure, in combination with cisplatin increased intracellular hydroxyl radicals in 
cholangiocarcinoma cells through disruption of lysosomal permeability and mitochondrial 
bioenergetics (314). Additionally, other laboratories have shown chloroquine may induce 
apoptosis via p53-dependent pathways leading to increased apoptosis, as well as accentuating 
mitochondrial fragmentation and dysfunction in already damaged mitochondria, an effect evident 
in irradiated cells (314–316). Given literature evidence and lack of radiosensitization with added 
models of autophagy inhibition, we concluded radiosensitivity exhibited by CQ was most likely a 
result of off-target or autophagy-independent effects. Despite modest sensitization to radiation in 
p53 wt cells exposed to chloroquine, the autophagy proved to be nonprotective in both cell lines 
in multiple additional pharmacological and genetic inhibition models. Nevertheless, the autophagy 
was far more extensive in the p53 wild-type cells than in the p53 null cells and this did not result 
in protection from radiation. In fact, the p53 wild-type cells were more radiation-sensitive than the 
cells lacking functional p53, thus supporting the argument that the promotion of autophagy does 
not uniformly translate to reduced radiation sensitivity. 
The major findings in these studies further complicate the role of p53 in radiation sensitivity. 
Previous studies demonstrate perturbation of p53 function could allow cancer cells to evade 
radiation-induced apoptosis, escape cell cycle checkpoints, and continue mitotic proliferation. 
For example, Hep3B2.1-7 hepatocellular cancer cells that lack p53 expression were less 
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radiosensitive than HepG2 cells with a functional p53 primarily due to attenuation in apoptosis 
induction (317). Similarly, Cheng et al. reported that induction of p53 expression in H1299 lung 
cancer cells resulted in enhanced radiosensitivity, again due to increased apoptosis induction 
(318). In the current work, H460 cells with functional p53 are also more radiosensitive than their 
p53-null counterparts; however, p53 status had no significant impact on apoptosis levels in 
response to radiation. Instead, our studies suggest that the difference in radiation sensitivity in the 
two cell lines may be largely due to their propensity to enter into a state of senescence, as was 
suggested by earlier work from our group relating to the involvement of p53 in chemotherapy-
induced senescence (243). 
Accumulating literature has shown that DNA-damaging events and ROS generation associated 
with radiotherapy can induce a premature senescence in tumor cells (259,319,320). Senescence 
activation allows tumor cells to undergo an alternative cell fate, aside from cell death, and provides 
an opportunity for cells to repair and potentially recover from DNA damage while halted in a cell 
cycle arrest (287). Furthermore, radiation-induced DNA damage can activate p53, resulting in 
senescence (300).  Luo et al showed that 6 Gy radiation did not induce significant apoptosis in 
A549 and H460 cells, but rather induced a premature senescence indicated by increased SA-b-gal 
staining. Furthermore, knockdown of p53 inhibited radiation-induced senescence, while 
restoration of p53 expression sensitized cells to radiation and induced senescence (232). In 
agreement, Widel et al have shown that induction of senescence differed in p53 +/+ and p53 -/- 
HCT116 cells, where the p53-deficient cells showed a significant reduction in the expression of 
senescence markers in comparison to the p53-proficients cell (321). However, in these studies p53 
-/- HCT116 cells exhibited a higher frequency of apoptosis compared to its counterpart, p53 +/+ 
HCT116 cells, which predominantly underwent senescence in response to irradiation.  The data 
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presented in our findings indicate that H460wt cells undergo senescence induction to a greater 
extent than H460crp53 cells, resulting in differences in radiosensitivity.  The spectrum of 
responses activated by radiation exposure adds complexity to the effects of p53 status on the 
toggling of cellular processes induced in response to therapy. 
As indicated above, tumor cells almost uniformly undergo autophagy in response to exogenous 
forms of stress such as chemotherapy and radiation. Although the bulk of the scientific literature 
tends to consider autophagy as a cytoprotective response to stress and as a mechanism of 
resistance, this premise is subject to a number of reservations. One is that autophagy is not 
uniformly cytoprotective; in fact, autophagy can exist in one of four functional forms, only one of 
which is protective; the other forms are cytotoxic, cytostatic, and nonprotective autophagy (Figure 
2.9) (117). Consequently, efforts to exploit autophagy inhibition as a therapeutic strategy for 
radiosensitization (or chemosensitization) are unlikely to be successful unless all autophagic 
responses to radiation, regardless of the tumor type, actually prove to be cytoprotective, which is 
highly unlikely based on our preclinical studies.  
An abundance of literature, including this study, demonstrates senescence induction in response 
to radiotherapy.  SASP secretion by these senescent cells can result in altered immune infiltration, 
activate senescence in neighboring cells, and promote changes in the ECM, priming the 
environment for a migratory phenotype (235). Moreover, promotion and recovery from senescence 
may be a potential model for tumor dormancy (271,322). Whether senescence is activated in 
response to radiation in clinical settings is not well understood and begs additional investigation. 
However, given the array of cellular responses induced in reaction to radiotherapy pre-clinically 
(Figure 2.9), it necessary to determine clinical patient tumor responses to further surmise whether 
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administration of an autophagy inhibitor or a senolytic, an agent that selectively clears senescent 
cells, may provide the more advantageous approach to radiosensitize patient tumors.  
While these studies provide pre-clinical evidence that tumor cells at least undergo apoptosis, 
autophagy and senescence in response to radiation, it is also necessary to consider the possibility 
of additional outcomes to radiotherapy such as mitotic catastrophe, necrosis, and necroptosis. 
Furthermore, the extent to which of these factors contribute to radiation sensitivity or resistance 
in a particular malignancy cannot be predicted in clinical settings and is likely to vary depending 








Figure 2.9. Tumor cell responses to radiotherapy.  
In response to radiotherapy, tumor cells can upregulate both cell death and cell survival pathways. 
Whereas apoptotic cell death is the ideal outcome for clinical therapeutic treatment, tumor cells 
often enter into senescence and autophagy, largely in efforts to evade cell death. However, 
radiation-induced autophagy can assume different functional roles.  Induction of the cytoprotective 
form of autophagy allows cells to evade apoptotic cell death and prolong survival; however, 
cytotoxic autophagy can facilitate either apoptotic and/or autophagic cell death. Finally, an 
alternative form of autophagy that does not appear to influence cell sensitivity to radiotherapy can 
occur, termed nonprotective autophagy. Senescence often occurs in parallel with autophagy, 
sharing a number of mechanistic regulators. Radiation-induced senescence allows cells to 
transiently arrest in efforts to repair damage. Subsequently, tumor cells may undergo apoptotic cell 
death if the extent of damage is excessive or may overcome the insult, allowing for continued 
survival. Senescence may also contribute to tumor dormancy, as a subset of senescent cells endure 
a prolonged growth arrest and regain proliferative capacity. Senescent cells produce a unique 
secretory phenotype (SASP), allowing for manipulation of the ECM and influencing surrounding 
cells in the TME. Through the release of specific cytokines and chemokines, autophagy and 
senescence can play immune-modulatory effects to create either immune-promoting or immune-
suppressive microenvironments, thereby contributing to overall tumor survival or clearance. Both 
autophagy and senescence have cell-autonomous, as well as cell non-autonomous effects, adding 
to the complexity of responses and outcomes of clinical radiotherapeutics.  
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Chapter Three: What is the effect of p53 status on cisplatin sensitivity 
and the nature of autophagy in NSCLC cells? 
3.1 Introduction 
Cisplatin is a commonly used anti-cancer therapy. It is prescribed for the treatment of a number of 
cancer types, including breast cancer, lung cancer, ovarian cancer, head and neck cancers, brain 
cancer, as well as many others (323). Cisplatin, like most platinum-based drugs, contains a 
platinum moiety which that forms covalent platinum-DNA interactions, generating both inter-and 
intrastrand crosslinks in the DNA (324). Formation of these adducts interferes with the proper 
binding of transcription factors and proteins required for DNA replication and DNA transcription 
for protein synthesis, ultimately resulting in cell cycle arrest and apoptosis (323). While cisplatin 
is a highly effective anti-cancer therapeutic, resistance to treatment still remains a prevalent issue. 
Several mechanisms have been proposed for cisplatin resistance, including drug efflux via the 
multi-drug resistance pump, DNA damage repair, and inhibition of apoptosis (325). Furthermore, 
in response to cisplatin treatment, it has been demonstrated that cells upregulate autophagy, a 
conventionally cytoprotective mechanism, and may contribute to cisplatin resistance in tumor cells 
(119).  
While it is indisputable that inhibition of cytoprotective autophagy proves an advantageous avenue 
for chemosensitization and radiosensitization (79,123,137), it is essential to acknowledge the 
multi-functional nature of autophagy in response to therapy (139,141,313). As exemplified from 
the previous studies on radiation, autophagy was nonprotective in function, regardless of p53 
status, indicating autophagy inhibition failed to sensitize cells to radiotherapy (142). Furthermore, 
previous work from our laboratory demonstrated the existence of an important phenomenon, which 
 78 
we have termed the “autophagic switch” where the functional form of autophagy can be changed 
to another form in response to external or biological stressors. In these studies, ZR-75-1 breast 
cancer cells, expressing wild type p53, exhibited cytoprotective autophagy when treated with 
radiation alone; however, when given in combination with 1,25-dihydroxy vitamin D3, the 
functional form of autophagy was “switched” to a cytotoxic form (326). Autophagic function may 
be regulated by several factors, including p53, oxidative stress, and genotoxic stress (19,51,327). 
Depending on the spatiotemporal localization of p53, it can both suppress and activate autophagy 
(328). Whether p53 plays a role in determining the nature of the autophagy is not yet understood; 
however, in this work, we attempt to further probe this question by utilizing a set of isogenic cell 
lines, H460wt and H460crp53 NSCLC cell lines, used previously in our studies relating to 
radiation. 
Cisplatin-induced DNA damage can result in the activation of p53 and, depending on the amount 
of damage, induce a multitude of cellular responses including senescence, autophagy, and 
apoptosis (104,329). Furthermore, loss of p53 is also associated with increased tolerance to 
cisplatin-induced DNA adducts and replicative bypass, contributing to cell survival and treatment 
resistance (325,329). From the studies presented in chapter 2 with radiation, p53 status plays a role 
in toggling between important cellular responses. In response to radiotherapy, senescence seemed 
to play a predominant role in mediating the differential radiation sensitivity between H460wt and 
H460crp53 cells. Similarly, senescence induction in response to cisplatin exposure has been 
demonstrated in ovarian, NSCLC, and melanoma cell lines (246,330,331).  Furthermore, cisplatin-
induced SASP secretion in senescent melanoma cells was shown to promote cellular growth in 
non-senescent counterparts (330). Thus, the current study paralleled the radiation studies to 
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examine the effects of p53 status on tumor cell responses to cisplatin exposure and whether the 
type of cytotoxic therapy affects autophagic function.  
 
3.2.  Methods 
3.2.1. Cell Culture and Treatment 
H460wt and H460crp53 NSCLC cells were cultured in DMEM media supplemented with 10% 
(v/v) fetal bovine serum (Thermo Scientific), 100 U/ml penicillin G sodium (Invitrogen), and 100 
μg/ml streptomycin sulfate (Invitrogen). Puromycin (1 μg/ml; Sigma) was used to maintain the 
selection of shATG5 and shControl transfected cells. Cells were incubated at 37℃ under 
humidified 5% CO2. Cisplatin was purchased from Cayman Chemical Company (13119) and 
dissolved in dimethylformamide to a stock solution of 10 mM. Working solutions were further 
diluted in media.   
Cells were seeded on day 0 followed by cisplatin treatment (0, 2.5, 5, 10, 20 μM) on day 1 for 24 
h. Media was replenished every other day.  For autophagy inhibition studies, cells were treated 
with pre-treated with 3MA (0 or 1 mM) or CQ (0 or 10 µM) 3 h prior to cisplatin (0 or 10 µM) 
exposure for 24 h. All assays performed as previously described. 
3.3 Results 
3.3.1.  Cisplatin sensitivity in H460wt and H460crp53 NSCLC cells 
In previous work, we reported that radiation-induced autophagy was nonprotective in the H460 
non-small cell lung cancer cell line regardless of p53 status (142). In order to investigate whether 
autophagy is universally nonprotective in this cell line, the current studies utilized the antitumor 
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drug, cisplatin, as the primary autophagy inducer. Furthermore, utilizing the same set of isogenic 
cell lines, H460wt and H460crp53 NSCLC cells, we aimed to discern the effects of p53 status on 
cisplatin sensitivity and autophagic function.  
Initially, cells were exposed to 10µM cisplatin for 24 hrs. Temporal analysis of cell viability was 
assessed to confirm the differential sensitivity to cisplatin. Figure 3.1A demonstrates that H460wt 
cells were more sensitive to 10 µM cisplatin exposure than H460crp53 cells. Temporal response 
pattern largely showed that the H460wt underwent a rapid growth decline, indicative of cell death, 
while the H460crp53 cells initially continue to proliferate and only begin to succumb to the drug 
effects after 3 days. 
It is generally thought that lack of p53 function attenuates apoptosis (289,332). An evaluation of 
the extent of apoptosis by annexin V/PI staining demonstrated that H460wt cells exposed to 
different doses of cisplatin underwent a much more pronounced degree of apoptosis/necrosis than 
H460crp53 cells (Figure 3.1B). This did not appear to be a consequence of differential DNA 
damage since cisplatin promoted equivalent DNA damage in the H460p53 wt and H460crp53 










Figure 3.1. Cisplatin sensitivity in H460wt cells and H460crp53 cells.  
A. Cell viability. Cells were treated with cisplatin (10 μM) for 24 h, washed free of drug, 
incubated with fresh medium and stained with trypan blue (n=3). B. Apoptosis Dose Response. 
Cells were treated with cisplatin at the indicated doses for 24 h and apoptosis was assessed by 
Annexin V-FITC staining. Apoptosis was measured 24 h after cisplatin removal (n=3). C-D. 
DNA Damage. Temporal assessment of DNA damage in response to cisplatin. Extent of DNA 
damage was measured utilizing flow cytometry to quantify γH2AX staining in cells treated with 
cisplatin (10 µM). (D) Representative images of flow cytometry data and (E) quantification of 
fluorescence was graphed (n=3). Unless stated, otherwise data were from three independent 
experiments, *p < 0.05, cisplatin treated H460wt group vs cisplatin treated H460crp53 group. #p 
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3.3.2. Cisplatin-induced autophagy in p53 wt and p53 knockout cells  
Cytoprotective autophagy is generally considered to be a mechanism to ameliorate or evade 
apoptosis; hence, we assessed the capacity of cisplatin to promote autophagy in both cell lines. 
Figure 3.2A presents images of acridine orange staining of autophagic vacuoles, a rough but 
generally accurate indication of the extent of autophagy. Assessment of acidic vesicle formation 
by flow cytometry indicated that the extent of autophagy induced by cisplatin was similar in the 
two cell lines (Figure 3.2B). To further compare the extent of autophagy and whether cisplatin-
induced autophagy is going to completion, degradation of p62/SQSTM1 was evaluated by 
western blotting. Figure 3.2C (and quantification of the band densities in Figure 3.2D) indicates 
that autophagic flux is clearly occurring in both cell lines. Moreover, both H460wt and 
H460crp53 cells demonstrate co-localization of LC3 and the lysosomal marker, LAMP-2, when 
exposed to cisplatin indicative of autophagic flux (Figure 3.2E). Consistent with the previous 
studies in radiation, untreated H460crp53 exhibited greater LC3/LAMP2 co-localization when 
compared to H460wt cells, suggesting basal autophagy was higher in H460crp53 cells. These 
studies indicate that autophagy appears to be induced to a similar extent in cisplatin-treated H460 





Figure 3.2. Cisplatin induces autophagy in H460wt cells and H460crp53 cells.  
A-E.Cells were treated with cisplatin at the indicated doses for 24 h (day 0), after which cells 
were washed and incubated in fresh medium. A. Acridine orange staining was performed after 
exposure to 10 μM cisplatin. Cells were treated with cisplatin for 24 h (day 0) and stained 48 h 
post-drug removal (day 3, n=3). B. Quantification of acridine orange staining. Autophagy 
induction was quantified by flow cytometry in response to increasing concentration of cisplatin 
2 days after drug exposure (n=3). C. Western blotting. Levels of p62 were determined by 
western blotting at the indicated times after 10 µM cisplatin exposure for 24 h (D0). Lysates were 
collected on indicated days. One of three representative experiments is shown (n=3). D. Western 
blot Densitometry. The bar graph in each panel indicates the relative band intensity generated 
from densitometric scans of two independent experiments in arbitrary densitometric units (n=3). 
E. Co-localization of LC3 and LAMP. Fluorescence microscopy showing LC3 and LAMP2 co-
localization in response to 10 µM cisplatin exposure 2 days after cisplatin removal. (20X 
objective, n=2) Unless stated, otherwise data were from three independent experiments, *p < 
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3.3.3. Evidence for cytoprotective autophagy in the p53 knock-out cells and nonprotective 
autophagy in the p53 wild-type H460 cells 
Next, the nature of the autophagy was evaluated based on sensitization or lack of sensitization 
when autophagy was inhibited using the pharmacological autophagy inhibitors, CQ or 3-MA. Both 
H460 cell lines were pre-treated with CQ (10 μM) or 3-MA (1 mM) for 3 h followed by exposure 
to 10 μM cisplatin for 24 h. Autophagy was measured after 2 days of incubation with fresh 
medium. The increase in LC3-II puncta formation in the presence of CQ (due to inhibition of 
autolysosome formation and accumulation of autophagosomes) and decrease in LC3-II puncta 
with 3-MA (due to interference with autophagosome formation) indicated that CQ and 3-MA 
inhibited cisplatin-induced autophagy (Figure 3.3A). Interference with p62/SQSTM1 degradation 
further confirmed that CQ and 3-MA inhibited cisplatin-induced autophagy (Figure 3.3B). 
Temporal response studies were then performed to determine the impact of autophagy inhibition 
on sensitivity to cisplatin. Figures 3.3D and 3.3E-F show that administration of CQ and 3-MA 
increased cell death and apoptosis in response to cisplatin in the H460crp53 cells but failed to 
influence cisplatin-induced cell death and apoptosis in the H460wt cells (Figure 3.3C and 3.3E-
F), indicating that autophagy was cytoprotective in function in the H460crp53 cells but 





Figure 3.3. Pharmacological autophagy inhibition sensitizes H460crp53 cells, but not H460wt 
cells to cisplatin exposure.  
A. Inhibition of autophagy by CQ and 3-MA. Fluorescence microscopy showing increased 
LC3 puncta following CQ (10 µM) co-treatment with 10 µM cisplatin, and decreased LC3 puncta 
following 3-MA (1 mM) co-treatment with 10 µM cisplatin. Cells were pretreated with CQ (10 
µM) and 3-MA (1 mM) followed by an additional 24 h with cisplatin. Images were taken 48 h 
after cisplatin removal. Nuclei were stained with Hoechst 33342 and vacuoles with LC3 antibody 
(20x objective, n=2). B. Inhibition of autophagy by CQ and 3-MA. Western blot showing 
autophagy blockade by CQ (10 µM) and 3-MA (1 mM) based on levels of p62/SQSTM1 (n=3). 
The bar graph in each panel indicates the relative band intensity generated from densitometric 
scans of two independent experiments in arbitrary densitometric units. C and D. Influence of 
autophagy inhibition on cisplatin sensitivity. Viability of H460wt cells and H460crp53 cells 
was monitored based on trypan blue exclusion at indicated days following 10 µM cisplatin 
exposure in combination with CQ (10 µM) or 3-MA (1 mM) (n=3). E-F. Influence of autophagy 
inhibition on cisplatin induced apoptosis. Annexin V-PI staining showing influence of CQ (10 
µM) and 3-MA (1 mM) on apoptosis of H460 cells exposed to cisplatin (10 µM). Cells were 
pretreated with CQ or 3-MA for 3 h followed by co-treatment with cisplatin for 24 h. Apoptosis 
was measured 24 h after cisplatin removal (n=3). Unless stated otherwise, data were from three 
independent experiments, *p<0.05, cisplatin versus cisplatin + CQ (3-MA).    
 86 
To confirm the findings generated using pharmacological inhibition, short hairpin RNA (shRNA) 
was used to knockdown Atg5, an autophagy regulatory gene, in both H460 cell lines. Figure 3.4A 
verifies the status of Atg5 by Western blotting in the two cell lines. The decrease in LC3 puncta 
(Figure 3.4B) indicates that shAtg5 effectively inhibited autophagy in both H460 cell lines. 
Inhibition of autophagy was confirmed by interference with cisplatin-induced degradation of 
p62/SQSTM1 (Figure 3.4C).  Here, genetic interfere with autophagy yielded a similar outcome 
to that observed with the pharmacological autophagy inhibitors; specifically, autophagy inhibition 
failed to alter growth inhibition and apoptosis in response to cisplatin in H460wt cells (Figures 
3.4D and 3.4E-F), but increased cell growth inhibition and apoptosis in the H460crp53 cells 
(Figures 3.4D and 3.4E-F).  
 
Taken together, these data demonstrate that in the H460wt cells the autophagy is nonprotective 
since there is no further sensitization with autophagy inhibition and no increase in apoptosis. In 
contrast, autophagy “switches” to the cytoprotective form/function when p53 is knocked out, as 





Figure 3.4. Influence of genetic autophagy inhibition on cisplatin sensitivity in H460wt cells 
and H460crp53 cells.  
A. Western blot showing the silencing of Atg5 in H460wt cells and H460crp53 cells. B and C. 
Autophagy inhibition by Atg5 silencing. The bar graph in each panel indicates the relative band 
intensity generated from densitometric scans of three independent experiments in arbitrary 
densitometric units (n=3). B. Fluorescence microscopy showing decreased LC3 puncta following 
treatment with 10 µM cisplatin in shAtg5 H460 cells. Images were taken 48 h after cisplatin 
removal. Nuclei were stained with Hoechst 33324 (20x objective, n=2). C. Western blot showing 
autophagy blockade by Atg5 knockdown based on levels of p62/SQSTM1. Proteins were collected 
48 h after cisplatin removal (n=2). The bar graph in each panel indicates the relative band intensity 
generated from densitometric scans of two independent experiments in arbitrary densitometric 
units. D. Influence of autophagy inhibition on cisplatin sensitivity. Viability of H460wt cells 
and H460crp53 cells was monitored based on trypan blue exclusion at indicated days following 
cisplatin exposure in shATG5 in H460wt cells and H460crp53 cells (n=3). E. Influence of 
autophagy inhibition on cisplatin induced apoptosis. Annexin V-PI staining showing apoptosis 
in H460 cells exposed to cisplatin (10 µM) with and without ATG5 silencing. Apoptosis was 
measured 24 h after cisplatin removal. (n=3). Unless stated otherwise, data were from three 
independent experiments, *p < 0.05, shControl + cisplatin versus shAtg5 + cisplatin, #p < 0.05, 
shControl versus shATG5. 
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3.3.4. Cisplatin induced senescence in H460wt and H460crp53 NSCLC cells  
Autophagy and senescence often occur in parallel in response to cytotoxic therapy. Given that 
senescence contributed to the differential sensitivity to radiotherapy in our previous studies (142);  
therefore, we investigated the role of senescence induction and its contributions to the differential 
sensitivity seen between H460wt and H460crp53 cells. Cells were exposed to 10 µM cisplatin and 
senescence-associated ß-galactosidase (SA-ß-gal) activity was assayed. Figure 3.5A demonstrates 
ß-galactosidase staining (blue) was increased in both H460wt and H460crp53 cells.  SA-ß-gal 
activity was also monitored by flow cytometry for a more quantitative approach. Temporal 
analysis of SA-ß-gal activity was increased in both cell lines in response to cisplatin exposure, 
indicating senescence was induced to similar extents in both the H460wt and H460crp53 NSCLC 






Figure 3.5. Cisplatin induced senescence in H460wt and H460crp53 NSCLC cells.  
A. β-galactosidase staining and cell morphology. β-galactosidase staining indicating the 
induction of senescence by cisplatin (10 µM) in both cell lines (scale bar = 20 μm). B. 
Quantification of senescence. C12FDG staining and flow cytometry to quantify the extent of 
senescence in H460wt and H460crp53 cells. Cisplatin induced senescence in both H460wt and 
H460crp53 cells. Unless stated, otherwise data were from three independent experiments. n.s. 
H460wt versus H460crp53 cells.  
  


























3.3.5. Inhibition of cytoprotective autophagy shifts the temporal response to cisplatin in the 
H460crp53 cells  
Given that senescence was induced to similar extents in both cell lines, we wanted to confirm the 
differential sensitivity to cisplatin exhibited between the two cells lines was partly due to 
differences in autophagic function. To examine the contributions of cytoprotective autophagy to 
cisplatin sensitivity, we compared the temporal responses shown in Fig. 3.3C and 3.3D with and 
without pharmacological autophagy inhibition by replotting these time courses in Figures 3.6A 
and 3.6B. The blockade of cytoprotective autophagy in H460crp53 cells exposed to cisplatin 
resulted in a temporal decline in cell viability that was essentially identical to that in the cisplatin 
treated H460 p53wt cells. In agreement with these observations, Figure 3.6C demonstrates a 
similar relationship when cell viability data from Fig. 3.4D is plotted together to show an overlap 
of the decline in cell viability in response to cisplatin when autophagy has been genetically 








Figure 3.6. Inhibition of cytoprotective autophagy shifts the temporal response to cisplatin 
in the H460crp53 cells.   
A-C. Influence of autophagy inhibition on cisplatin sensitivity in p53 wt and p53 KO cells. 
Cell viability data from figure 3C and 3D were overlaid to compare the functional role of 
autophagy in H460crp53 and H460wt cells using the pharmacological inhibitors, CQ (A) and 
3MA (B). C. Cell viability data from figure 4D were overlaid to compare the functional role of 
autophagy on cisplatin sensitivity via genetic silencing of ATG5.  *p<0.05 p53wt shControl + cis 










Figure 3.7. Cellular responses to cisplatin exposure in H460wt and H460crp53 NSCLC cells. 
 
In response to cisplatin exposure, H460wt cells were significantly more sensitive than H460crp53 
cells. H460wt cells underwent greater apoptosis induction compared to H460crp53 cells; however, 
the extent of autophagy induction and senescence induction was similar in the two cell lines. 
Autophagy inhibition revealed H460wt cells underwent nonprotective autophagy, while 
H460crp53 cells induced cytoprotective autophagy. These data demonstrated nonprotective 
autophagy induced in p53wt non-small cell lung cancer cells in response to cisplatin can be 
“switched” to protective autophagy in isogenic crp53 cells, and that inhibition of cytoprotective 
autophagy is sufficient to restore cisplatin sensitivity in the crp53 cells, through the promotion of 





Autophagy is one mechanism thought to be induced by cancer cells to evade apoptosis (333). 
Cisplatin exposure resulted in autophagy induction to a similar extent in both the H460wt and 
H460crp53 cells. Autophagy inhibition (by pharmacological and genetic interventions) increased 
cisplatin-induced cell death and apoptosis in H460crp53 cells (i.e., evidence of cytoprotective 
autophagy) but did not alter either outcome in the p53 wt H460 cells (i.e. evidence of 
nonprotective autophagy). As a result, the temporal decline in cell viability in the H460crp53 
cells when autophagy was inhibited essentially paralleled that observed in p53 wt H460 cells, 
suggesting cytoprotective autophagy was contributing to the differential sensitivity and differing 
extent of apoptosis observed between the two cell lines when exposed to cisplatin. Consequently, 
these findings support the premise that cytoprotective autophagy can confer a relative degree of 
resistance to chemotherapy. 
This work further interrogates the relative contributions of p53 status and autophagy to sensitivity 
and resistance to chemotherapy. Tasdemir et al and colleagues had reported that inhibition of 
cytoplasmic p53 led to autophagy in enucleated cells and conversely that cytoplasmic p53 was 
able to repress the enhanced autophagy of p53 null cells, providing evidence of a relationship 
between p53 and autophagy (170). Topotecan, a topoisomerase I inhibitor, induced cytoprotective 
autophagy in p53wt colon cancer cells in vitro and in vivo, but induced cytotoxic autophagy in 
p53 null colon cancer cells (334). Tripathi et al. demonstrated that cisplatin induced protective 
autophagy in p53 knockdown embryonal carcinoma cells, which would be consistent with the 
findings presented in this work (169). However, Maycotte et al reported on nonprotective 
autophagy in p53 null 4T1 breast tumor cells exposed to cisplatin (298). These differential 
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outcomes indicate that it cannot be predicted, a priori, the nature that drug or radiation-induced 
autophagy will exhibit, based solely on the status of p53 in the cells.  
 
 
The Autophagic Switch. Collectively, autophagy can play various functional roles in response to 
chemotherapy and radiation; moreover, the mechanism(s) determining the functional form induced 
in response to therapy still remains unclear. To add further complexity to these observations, a 
unique phenomenon whereby autophagy can “switch” between functions has also been 
demonstrated (141,142,326). For instance, the “autophagic switch” was also exhibited in studies 
of estrogen receptor (ER) expression in breast cancer cells exposed to gemcitabine (335). 
Gemcitabine induced cytoprotective autophagy in ER- BCap37 breast cancer cells, but cytotoxic 
autophagy in ER+ Bcap37 cells. Further, genetic silencing of the ERa receptor in the ER+ Bcap37 
cells was sufficient to switch the cytotoxic form of autophagy to the cytoprotective form. In an 
osteosarcoma model, drug-resistant cells exhibited cytoprotective autophagy, with greater reliance 
on autophagy for metabolic maintenance, whereas, drug-sensitive cells exhibited cytotoxic 
autophagy in response to camptothecin (336).  The studies presented with cisplatin and 
radiotherapy in the same set of isogenic H460 NSCLC cell lines provide further evidence of the 
existence of an “autophagic switch” in tumor cells in response to anti-cancer therapy. 
In the current work, cisplatin induced similar levels of autophagy in both p53 wt and H460crp53 
cells, indicating that the capacity to undergo cisplatin-induced autophagy is essentially p53-
independent. However, as in many of the studies cited above, the nature of the autophagy changed 
in association with the different p53 statuses of the two cell lines. Inhibition of autophagy 
increased drug sensitivity and apoptosis in the H460crp53 cell to similar extents as p53wt cells 
exposed to cisplatin. This critical observation from the current work suggests that cells lacking 
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functional p53 are capable of undergoing apoptosis to the same degree as p53 wild-type cells.  
As was shown in Figure 3.6, autophagy inhibition in H460crp53 cells shifted the temporal 
response to cisplatin to be virtually identical to that in the H460wt cells, suggesting that 
cytoprotective autophagy and not p53 function was largely responsible for the reduced sensitivity 
to cisplatin of the crp53 cells (Figure 3.7).  
Interestingly, this differs from our recent findings in studies involving ionizing radiation, where 
radiation sensitivity appeared to be a function primarily of the extent of senescence and appeared 
to be largely unrelated to autophagy (337) (Table 3.1). In these studies, the same set of isogenic 
cell lines, H460wt and H460crp53 cells, exhibited nonprotective autophagy in both cells when 
exposed to radiation and autophagy inhibition failed to alter radiation sensitivity or radiation-
induced apoptosis in either cell line. However, through these studies, we demonstrate that crp53 
cells have the capacity to undergo nonprotective autophagy (in the case of radiation), and this 
response is “switched” to protective autophagy in the case of cisplatin treatment (Table 3.1). 
Collectively, these studies suggest the existence of an autophagic switch, not only between 
isogenic cell lines differing in p53 status but also depending on the therapeutic agent utilized.  
 
While these studies with H460wt and H460crp53 cells isogenic cell lines exposed to radiation or 
chemotherapy demonstrated functional switches in autophagy, both in terms of cytotoxic agent 
and p53 status, very little is understood as to the mechanisms regulating autophagic function. DNA 
damage is the primary mechanism through which both radiation and cisplatin exert their antitumor 
effects. Furthermore, autophagy is induced in response to both anti-cancer treatments and aids in 
the turnover of proteins involved in DDR and cell cycle checkpoints (296). Below we consider 
whether the extent and/or temporal profile of DNA damage may contribute to the differential 
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functions of autophagy induced in response to cisplatin and radiation in H460wt versus H460crp53 
cells. The extent of DNA damage was similar in both cell lines when exposed to radiation or 
cisplatin; however, there were differences in the temporal profile of DNA damage incurred 
between the two treatment modalities (Figure 3.8). Radiotherapy induced maximal DNA damage 
around 30 mins-1 h post-IR exposure which seemed to resolve to basal levels within 24 h post-IR; 
in contrast, cisplatin demonstrated a delayed and much lower extent of DNA damage, but one that 













Figure 3.8. Radiation and Cisplatin induced DNA damage in H460wt and H460crp53 cells.  
A. Radiation-induced DNA damage. Cells were exposed to 6 Gy radiation and DNA damage 
was measured by 𝛾-H2AX staining. Fluorescence of 𝛾-H2AX was quantified using flow 
cytometry. B. Cisplatin-induced DNA damage. Cells were exposed to 10M of cisplatin for 24 
h and DNA damage was measured by 𝛾-H2AX staining throughout the 24 h exposure time. 
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A potential factor contributing to resistance to therapy is that in tumor cells with higher basal 
autophagy, autophagy may facilitate the removal of therapy-induced damage more efficiently. 
Studies by Liang et al. examining the role of autophagy in multidrug-resistant ovarian carcinoma 
observed that radiation induced relatively low levels of apoptosis; inhibition of apoptosis with 
ZVAD did not significantly alter survival or cell death, confirming that apoptosis is not the primary 
therapeutic response to radiation, at least in this experimental model (126). These studies also 
demonstrated higher basal autophagy in the multidrug-resistant phenotype SKVCR cells compared 
to human SKOV3 ovarian carcinoma cells, suggestive of a cytoprotective function. Moreover, 
inhibition of autophagy with 3-MA sensitized the multidrug-resistant cells to radiation while 
having only modest effects on the parental SKOV3 cells. Similarly, when examining LC3/LAMP2 
colocalization in untreated control cells in figures 2.3D and 3.2E, H460crp53 cells exhibit greater 
LC3 fluorescence compared to H460wt NSCLC cells, allowing initial indications that basal 
autophagy may be higher in H460crp53 cells compared to H460wt cells. While further 
examination is required, this difference in basal autophagy may play a role in the differences in 
autophagic function exhibited between the two cell lines in response to cisplatin. The lower and 
more delayed extent of DNA damage in response to cisplatin exposure may allow H460crp53, 
with higher basal autophagy, to maintain sufficient clearance of cisplatin-induced damage, 
sustaining cells below critical cell death thresholds.  
Inhibition of cytoprotective autophagy in the H460crp53 cells in response to cisplatin restored 
apoptosis induction and cisplatin sensitivity to similar extents as H460wt cells, where the 
autophagy was nonprotective, suggesting the crosstalk between autophagy and apoptosis may play 
a key role (73). One possibility is that autophagy may sequester and remove damaged mitochondria 
through mitophagy, preventing cytochrome C release and activation of intrinsic death pathways 
 99 
(338). Another potential mechanism through which autophagy modulates apoptosis is through 
selective cargo shuttling and degradation of pro-apoptotic proteins. Autophagy can mediate the 
degradation of caspase 8 and evade caspase 8-mediated cell death; furthermore, deficiencies in 
autophagy can also result in caspase 8 dimerization on the membrane of the autophagosome and 
promote TRAIL-mediated cell death (339,340).  Similarly, Wang et al. demonstrated NOXA, a 
BH3-only member of the Bcl2 family that promotes apoptosis, is targeted by p62 for autophagic 
degradation, reducing apoptotic induction in NSCLC and colorectal cancer cell lines (341). 
Autophagy inhibition increased NOXA protein accumulation, suppressed tumor growth, and 
activated cell death pathways (341). Thus, if autophagy was cytoprotective in nature due to its 
capabilities of trafficking pro-apoptotic proteins, then it could be hypothesized that autophagy 
inhibition would relieve this sequestration and switch responses to a pro-apoptotic cell fate. Future 
studies focusing on in-depth analysis of autophagic cargo may provide promising insights on the 
role of specific cargo on the nature of autophagic function and maybe a potential rationale for why 
one functional form of autophagy “switches” to another as exhibited in the H460crp53 cells.   
 
Taken together, these studies provide proof of concept that cytoprotective autophagy can confer 
intrinsic resistance to chemotherapy, based on a comparison of cisplatin sensitivity in two 
isogenic cell lines where autophagy demonstrated cytoprotective and nonprotective functions. 
However, it is necessary to recognize that autophagy induced by chemotherapy or radiation may 
not always be cytoprotective in the clinic and the therapeutic benefit of autophagy inhibition may 
only be successful in scenarios where the autophagy is cytoprotective. These studies further 
provide an additional model of the “autophagic switch” in cancer therapy using a set of isogenic 
cell lines, but the mechanistic basis for the autophagic switch still remains to be determined. 
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While these studies with cisplatin indicate p53 status may influence autophagic function, 
collectively taking the findings of both the radiation and cisplatin studies as a whole suggest that 
it cannot be predicted whether therapy-induced autophagy will be protective or nonprotective 
based solely on functional p53 status. If autophagy inhibition is to be incorporated into therapeutic 
intervention, it will likely be necessary to identify the functional form(s) of autophagy for each 
therapeutic intervention in a particular patient (i.e. personalized medicine), reiterating the 
importance of screening prior to the inclusion of autophagic inhibitors to clinical regimens (285).    
 
 
Table 3.1. Tumor responses to radiation and cisplatin exposure in H460wt and 




Chapter Four: What are the contributions of nonprotective autophagy 
to senescence? 
4.1 Introduction  
Autophagy and senescence are both activated in response to radiotherapy and chemotherapy, often 
concomitantly in tumor cells exposed to anti-cancer therapy as shown in the studies presented 
within this dissertation (142,342). Given the coexistence of autophagy and senescence in response 
to therapy and overlapping mechanistic triggers, it is necessary to gain further insights into the 
relationship between the two processes.  
Initiation of autophagy and senescence can be achieved through a number of cellular stress 
regulators, including p53, ROS, and mTOR (134,168,280,300,343,344) (Figure 4.1). Therapy-
induced damage activates p53, an essential tumor suppressor and stress sensor that can modulate 
the activity of both senescence and autophagy. p53 regulates a vast number of cellular processes, 
including by not limited to apoptosis, autophagy, and senescence. p53 mediates the transcription 
of a number of cell cycle inhibitors, including p21waf1 and p16, which inhibit the interaction 
between cyclins and cyclin-dependent kinases and induce cell cycle arrest (345). Luo et al. 
demonstrated that p53 activation using Nutlin-3a radiosensitized H1299 (p53 null) cells by 
activating p53-p21waf1 pathways and inducing cellular senescence (232). Furthermore, depending 
on the cellular localization of p53, nuclear p53 can activate autophagy through the transcriptional 
regulation of key ATG proteins or directly stimulate autophagy through DRAM (346). In contrast, 
cytoplasmic p53 mediates an inhibitory effect on autophagy through ubiquitin-mediated beclin1 
degradation and inhibition of AMPK (169,170). Another common meditator of both autophagy 
and senescence is oxidative stress. Anti-cancer therapies, such as radiation and cisplatin, can result 
in increased ROS levels due to mitochondrial dysfunction and uncoupling, as well as genotoxic 
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stress. Autophagy serves to alleviate the cellular burden of the damaged proteins and mitochondria 
and to remove stressors, such as damaged mitochondrial DNA (mtDNA), which may stimulate 
senescence induction (347–349). While autophagy is induced in response to oxidative stress, 
prolonged autophagy impairment in the presence of oxidative stress can result in senescence 
induction (343,350). Furthermore, excessive ROS accumulation can further exacerbate DNA 
damage, resulting in p53/p21Cip1 activation and promotion of senescence (227,319,351,352). 
Taken together, pathways activated in response to therapy-induced damage can regulate both 
autophagy and senescence. 
Additionally, mTOR is an important regulator of both senescence and autophagy. mTOR prevents 
activation of autophagy initialization; thus, mTOR inhibition has been shown to upregulate 
autophagy (134,353). Studies by Nam et al demonstrated autophagy activation in response to 
mTOR inhibition in glioma, lung, colorectal, and breast cancer cell lines when exposed to 
radiotherapy; furthermore, mTOR blockade (which promotes autophagy) resulted in premature 
senescence and restoration of radiosensitivity (354). Seminal work by Narita et al. showed that 
mTOR and autophagic machinery may be important in SASP processing during senescence 
(178,355). The authors observed a specialized compartment, which they termed the TOR-
autophagy spatial coupling compartment (TSACC), where products of cellular catabolic processes, 
such as autophagic degradation could feed into cellular anabolic processes, to promote protein 
synthesis. Disruption of mTOR localization to TSACC was shown to inhibit interleukin-6/8 
synthesis in Ras-induced senescence, suggesting that autophagy may play a role in SASP 
generation, which can reinforce the senescent phenotype.  
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A plethora of anticancer therapies and concomitant stress pathways activate both autophagy and 
senescence as alternative cell fates in response to genotoxic and oxidative stress induced by 
clinically relevant doses of anti-cancer agents; however, whether autophagy and senescence are 
interdependent still remains elusive and further inquiry is necessary. Given that both autophagy 
and senescence are currently being examined as attractive means for tumor sensitization to therapy, 
it is important to understand the relationship between the two processes in order to gauge which 
pathway could be manipulated to provide a more favorable therapeutic outcome. In these studies, 
we delved deeper into the role of autophagy in senescence maintenance and recovery from the 
growth-arrested phenotype in HCT116 cells exposed to radiotherapy. One intrinsic limitation in 
studies aiming to address the relationship between autophagy and senescence is that in the case of 
cytoprotective autophagy, autophagy inhibition results in apoptosis, as exemplified both in the 
literature and studies within this dissertation (142,211); consequently, it becomes difficult to 
distinguish whether the exhibited responses are due to the impact of autophagy inhibition on cell 
killing or direct effects of autophagy inhibition on senescence. In an effort to circumvent this 
limitation, these studies examined the effects of nonprotective autophagy on senescence induction 
and recovery from the senescent phenotype, since by definition blockade of nonprotective 




Figure 4.1. Interconnectivity of cellular senescent and autophagic pathways.  
Given that both autophagy and senescence are two pathways activated by cellular stress and 
damage, it is plausible and well-exhibited in pre-clinical models that the two processes often occur 
in parallel in response to chemotherapy and radiation. Both autophagy and senescence converge 
on several molecular signaling pathways and share multiple regulators, such as p53, mTOR, and 
ROS. DNA damage induced by genotoxic therapies, such as etoposide, cisplatin, or radiotherapy, 
is recognized by ATM and results in its subsequent phosphorylation. Phosphorylated ATM 
activates DDR pathways, as well as initiates signaling cascades for p53 phosphorylation and 
activation. Activated p53 regulates a number of responses, including p21 induction resulting in 
cellular growth arrest and senescence, as well as transcription of proapoptotic proteins. 
Furthermore, subcellular localization of p53 can also modulate autophagy. Nuclear p53 and 
DRAM/p53 signaling axis leads to increased transcription of autophagic machinery; whereas 
cytoplasmic p53 can block autophagy induction and promote apoptosis and growth arrest. 
Anticancer therapies increasing intracellular ROS levels and inducing mitochondrial dysfunction 
can result in upregulation of mitophagy. Clearance of dysfunctional and aged mitochondria can 
prevent senescence, which occurs due to damage accumulation and oxidative stress. Moreover, 
elevated ROS levels can exacerbate DNA damage activating cellular growth arrest and apoptotic 
pathways. Lastly, autophagy may contribute to the senescent phenotype through the processing of 
SASP factors, such as IL-6 and IL-8, via a specialized compartment, TASCC, in which products 
from the cells catabolic autophagic processes provide raw materials for the anabolic protein 
synthesis processes. Collectively, while both autophagy and senescence are induced in parallel in 
response to anti-cancer therapeutics, whether the two processes are interdependent still remains 
elusive and requires further inquiry. Created with BioRender.com. 
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4.2.  Methods 
4.2.1. Cell Culture and Treatment 
HCT116 were generously provided by Dr. Sarah Spiegel, at Virginia Commonwealth University. 
HCT116 cells were cultured in RPMI both supplemented with 10% (v/v) fetal bovine serum 
(Thermo Scientific, SH30066.03), 100 U/mL penicillin G sodium (Invitrogen, 15140–122), and 
100 μg/mL streptomycin sulfate (Invitrogen, 15140–122). Cells were maintained at 37 °C under a 
humidified, 5% CO2 atmosphere at sub-confluent densities. 
The ATG5-knockdown was generated as follows: Mission shRNA bacterial stocks for ATG5 
were purchased from Sigma Aldrich. Lentiviruses were produced in HEK 293T cells co-
transfected using EndoFectinTM Lenti Transfection Reagent (GeneCopoeia, 1001-01) with a 
packaging mixture of psPAX2 and pMD2.G constructs (Addgene). Media containing the viruses 
was used to infect the HCT116 cells; puromycin (1 μg/ml) was used as a selection marker to 
enrich for the infected cells.  
 
Cells were seeded on day 0 followed by irradiation (0,2,4,6, 8 or 10 Gy) on day 1 utilizing a 137Cs 
irradiator. Media was replenished every other day. For autophagy inhibition studies, cells were 
treated with pre-treated with CQ (0 or 10 µM) 3 h prior to IR (0 or 4 Gy) exposure. All assays 




4.3.1. Radiation induced senescence and autophagy in HCT116 cells 
Cells were exposed to varying doses of radiation, media was replenished, and cells were stained 
with either X-gal or C12FDG to monitor senescence induction or acridine orange to monitor 
autophagy induction 72 h post-IR. Figures 4.2A-B show the collateral, parallel and dose-









Figure 4.2. The induction of senescence and autophagy in HCT116 cells in response to 
radiation.  
A.  SA-β-galactosidase staining of HCT116 cells treated with 4 Gy radiation demonstrating 
induction of senescence (20x objective). Fluorescence was quantified using flow cytometry 72 h 
post-irradiation. B. Fluorescent microscopy images of acridine orange staining 48 hours post-
radiation (4 Gy). Increased acidic vesicle formation is visualized (20x objective). Fluorescence 
was quantified using flow cytometry 72 h post-irradiation (n=2). Results presented were from three 
independent experiments, unless otherwise indicated.  
  
Control IR (4 Gy) A. 
B. Control IR (4 Gy) 
 


















4.3.2. Radiation induced nonprotective autophagy in HCT116 colorectal cells 
Autophagy was pharmacologically inhibited using CQ to assess the impact of autophagy inhibition 
on senescence induction and recovery. Specifically, HCT116 cells were pretreated with CQ (5 
µM) for 3 hours before being irradiated and then maintained in culture medium for an additional 
24 hours. Failure of lysosomal acidification in cells treated with CQ was demonstrated through the 
yellow staining of autophagic vacuoles (Figure 4.3A). Moreover, inhibition of autophagy was 
confirmed via western blot analysis demonstrating accumulation of the p62 protein levels with 
prior CQ exposure. (Figure 4.3B). Pharmacological inhibition of autophagy by CQ did not alter 
the sensitivity of HCT116 cells to radiation and did not promote radiation-induced growth arrest 
(Figures 4.3C). Autophagy inhibition also failed to alter radiation-induced apoptosis (Figure 
4.3D). Collectively, autophagy exhibited a nonprotective function HCT116 colorectal cells in 
response to radiotherapy; furthermore, these data are consistent with the previous studies with 
H460 NSCLC cells in which nonprotective autophagy was induced in response to radiation in this 













Figure 4.3. Radiation induced nonprotective autophagy in HCT116 colorectal cells. 
A-E. Cells were pre-treated with CQ (5 µM) 3 h prior to radiation (4 Gy) exposure. Media was 
replenished 24 h post-treatment. A. Acridine orange staining indicating blockade of lysosomal 
fusion in cells pre-treated with CQ (20x objective). B. Western blot analysis demonstrating 
autophagy blockade via p62 accumulation in cells pre-treated with CQ (n=2). C. Cells were treated 
with 4 Gy radiation alone or with CQ pre-treatment, and viable cell number was assessed via trypan 
blue exclusion on the indicated days. D. Annexin 5/PI staining was used to assess apoptosis 48 h 
post-radiation [radiation (4 Gy) alone or with CQ (5 µM) pre-treatment]. Autophagy blockade did 
not alter radiation-induced apoptosis (n = 2). Results presented were from three independent 




































































4.3.3. Senescence induction and recovery from growth arrest was independent of autophagy 
in HCT116 cells exposed to radiation 
As shown in Figure 4.4A-B, senescence induced by radiation in the HCT116 cells was not affected 
by autophagy inhibition. Figures 4.4C shows that HCT116 cells underwent growth arrest followed 
by proliferative recovery upon exposure to radiation, where HCT116 cells proliferative recovery 
was evident 3 days after radiation exposure. Furthermore, growth arrest and proliferative recovery 















Figure 4.4. Pharmacological autophagy inhibition did not alter senescence induction or 
recovery in HCT116 cells exposed to radiation.   
A. SA-β-galactosidase staining demonstrating increased SA-β-galactosidase activity in both cells 
exposed to radiation alone or pre-treated with CQ prior to radiation. B. SA-β-galactosidase activity 
was monitored by measuring C12FDG staining using flow cytometry. C. Cell viability data from 
figure 2D. The expanded scale for the lower portion of the graph is shown to visualize proliferative 
recovery from senescent growth arrest. Results presented were from three independent 






























































Finally, short hairpin RNA was utilized to knockdown ATG5 to assess the effect of genetic 
autophagy inhibition (silencing of ATG5, Figure 5A) on senescence induction and maintenance. 
In agreement with the pharmacological inhiation data, genetic interference of autophagy did not 




While the data is not shown in this dissertation, these studies were also performed with H460 (p53 
wt) NSCLC cells and 4T1 (p53 null) breast cancer cells exposed to etoposide and doxorubicin, 
respectively (251). Consistent with the HCT116 studies, doxorubicin and etoposide exposure 
induced both senescence and autophagy in H460 NSCLC and 4T1 breast cancer cells; moreover, 
both of these DNA-damaging chemotherapies induced nonprotective autophagy. Pharmacological 
and genetic autophagy interference did not alter senescence induction or proliferative recovery 
from the senescent state. Collectively, H460 NSCLC cells, 4T1 breast cancer cells, and HCT116 
colorectal cells exhibited nonprotective autophagy in response to etoposide, doxorubicin, and 
radiation, respectively. Further, nonprotective autophagy did not significantly contribute to 





Figure 4.5. Genetic autophagy inhibition did not alter senescence induction or recovery in 
HCT116 cells exposed to radiation.   
A. Western blot demonstrating ATG5 knockdown. B-C. Viable cell number was assessed in shControl and 
shATG5 HCT116 cells exposed to 4 Gy radiation. Representative curves of three independent studies are 
shown (n = 3). Results presented were from three independent experiments, unless otherwise indicated. n.s. 




























































4.4.  Discussion  
 
While autophagy and senescence often occur concomitantly in response to chemotherapy and 
radiotherapy, very little is understood on whether these two processes are interdependent. These 
studies, utilizing multiple cytotoxic therapies and multiple cell lines, demonstrated senescence 
induction and proliferative recovery are independent of autophagy when the autophagy is 
“nonprotective” in function (251). Furthermore, we observed that autophagy inhibition did not 
alter the extent of senescence induction or recovery in HCT116 colorectal carcinoma cells exposed 
to 4 Gy radiation. In these studies, at least in the scenario of nonprotective autophagy where 
senescence is the predominant response, it is feasible to speculate that while autophagy may be 
induced in a “conventional” effort to maintain survival, the senescence response predominates in 
conferring a survival advantage to the cells.  Whether autophagy contributes to the senescent 
phenotype or is a relic of senescence is not fully understood; however, these studies indicate that 
at least in scenarios where the autophagy is nonprotective, senescence induction and recovery is 
not reliant on autophagy. Alternatively, Vijayaraghavan et al. examined the effects of autophagy 
inhibition in breast cancer cells exposed to hormonal therapy in combination with CDK 4/6 
inhibitors (356). These authors demonstrated that autophagy inhibition significantly reduced cell 
viability and tumor burden of breast tumors exposed to Palbociclib, as well as the combination of 
Palbociclib and letrozole, suggesting that autophagy was cytoprotective in function. Furthermore, 
this sensitization resulting from the administration of an autophagy inhibitor in combination with 
Palbociclib was mediated through the synergistic induction of senescence. However, the studies 
by Vijayaraghavan et al. suggest autophagy and senescence may share an inverse relationship, 
complicating the association between the two processes as well as those originally proposed by 
 115 
Young et al. in which blockade of autophagy was shown to suppress senescence in a model of 
oncogene-induced senescence (357,358).  
Building on the previously established literature that autophagy may be a component for the 
maintenance of the senescent phenotype, autophagy inhibitors have been proposed as potential 
agents to clear senescent cells. Was et al. demonstrated exposure to BafA1 in doxorubicin-induced 
senescent HCT116 cells reduced cell viability and delayed tumor cell repopulation in the short-
term; however, in the long run, single pulse BafA1 exposure resulted in re-activation of autophagy 
and increased proliferation in the HCT116 recovering subpopulation in vitro and increased tumor-
burden in vivo when compared to chemotherapy alone (359). Therefore, while autophagy 
inhibitors may be an alluring therapeutic for the clearance of senescent cells, further studies 
elucidating the nature behind the contributions of autophagy to the senescent phenotype are 
necessary. In another closely related study, Vera-Ramirez et al. showed autophagy inhibition with 
HCQ decreased survival of dormant breast cancer cells and reduced lung metastasis; however, 
HCQ administration was minimally effective once dormant cells had regained proliferative 
capacity, suggesting the role of autophagy in sustaining tumor dormancy in breast cancer cells 
(360). While the extent of senescence was not assessed in these studies, senescence may a potential 
tumor dormancy model and further studies are warranted interrogating the contributions of 
autophagy in senescence-associated tumor dormancy and recovery (209).  Alternatively, aberrant 
activation of autophagy may serve as a potential senolytic.  Studies by Wakita et al. demonstrated 
that administration of a BET inhibitor, ARV825, cleared oncogene-induced senescent cells, as well 
as doxorubicin-induced senescent HCT116 colorectal cells in vitro and in vivo (361). Furthermore, 
the authors showed the senolytic capabilities of ARV825 were partially mediated through 
autophagy modulation. Genetic and pharmacological blockade of autophagy compromised 
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ARV825-induced senolysis, indicating autophagy was necessary for senescent cell clearance by 
the BET inhibitor (361).  
 
The tumor suppressor gene, TP53, coding for p53, regulates cellular mechanisms modulating both 
autophagy and senescence, as well as various other cell fates. Whether p53 is important in toggling 
cellular responses between senescence and autophagy is not well understood; however, our studies, 
albeit indirectly, provide some insights on the role of p53 status on autophagy and senescence 
induction. H460 NSCLC cells and HCT116 colorectal cells, expressing wild type p53, and 4T1 
breast cancer cells, which are null in p53 status, underwent senescence and autophagy to similar 
extents in response to etoposide, radiation, and doxorubicin, respectively. Regardless of p53 status 
and therapeutic exposure, all three cell lines underwent nonprotective autophagy; this concurs with 
our earlier conclusion that while p53 status may influence the function of autophagy, the specific 
function induced is inconsistent. Along the same lines of investigation, Sui et al. examined the 
effect of p53 status on autophagy and senescence induction in HCT116 under serum-starved 
conditions (362). Under serum starvation, HCT116 p53+/+ cells exhibited significantly greater 
autophagic flux than HCT116 p53-/- colorectal cells and protected p53 wild-type cells from 
starvation-induced cell death. Moreover, HCT116 p53+/+ cells underwent autophagy and 
quiescence in response to serum starvation, while HCT116 p53-/- cells induced senescence to a 
greater extent than p53 wild-type cells (362). Autophagy inhibition in HCT116 p53+/+ cells 
demonstrated cytoprotective autophagy in response to serum starvation, as expected, and increased 
ß-gal staining, indicating inhibition of cytoprotective autophagy enhanced senescence induction in 
HCT116 p53+/+ cells. However, autophagy inhibition did not alter senescence induction in 
HCT116 p53-/- cell (362). Collectively, these studies reiterate the ability of tumor cells to toggle 
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between cellular responses, the inconsistency of p53 status as a predictive marker for senescence 
induction and autophagy function, as well as the complexity underlying the relationship between 
autophagy and senescence. 
 
Summary The premise that autophagy confers resistance to various treatment modalities has been 
the basis for ongoing clinical trials combining chemotherapy or radiation; however, there are a 
number of conceptual and experimental reservations relating to these clinical trial strategies. One 
is that, as we and others have shown in multiple publications, autophagy is not uniformly 
cytoprotective, often exhibiting cytotoxic and non-protective functions. In scenarios where 
autophagy inhibition may be beneficial (i.e., when autophagy is cytoprotective in function), from 
a directly clinical perspective, it is highly uncertain whether chloroquine and hydroxychloroquine 
can achieve levels in the circulation and the tumor to sufficiently inhibit autophagy to the extent 
necessary for radiosensitization or chemosensitization. Finally, if and when more efficacious 
autophagy inhibitors are identified, it is necessary to acknowledge that autophagy also provides 
homeostatic regulation in normal tissues such as the central nervous system, and therefore 
autophagy inhibition might represent a double-edged sword that would induce unanticipated and 
undesirable (intolerable) toxicities.  
 
While autophagy plays a role in initial sensitivity to radiation and chemotherapy in tumor cells, 
accumulating literature has supported the induction of a prolonged growth arrest, characteristic of 
senescence, as a response to radiation and chemotherapy. Furthermore, a subset of these senescent 
cells is capable of regaining proliferative capacity, a possible contributor to tumor dormancy and 
disease recurrence. Consequently, senescent growth arrest may provide a significant contribution 
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to chemotherapy and radiation resistance and disease reemergence. Though the implications of 
senescence cannot be truly resolved due to a lack of effective inhibitors of senescence induction, 
senolytics may provide a novel class of therapeutics to add to the arsenal of cancer chemotherapy 
in attempts to eliminate senescent cancer cells. Moreover, given the fact that autophagy and 
senescence often occur in tandem, it is also important to gain insights as to the predominant 
responses activated to evade cell death in response to the respective anti-cancer regiment in order 
to determine whether incorporation of either an autophagy inhibitor or a senolytic with anti-
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